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A B S T R A C T
Background
Tuberculosis causesmore deaths than any other infectious disease globally. Bacillus Calmette-Guérin (BCG) is the only available vaccine,
but protection is incomplete and variable. The modified Vaccinia Ankara virus expressing antigen 85A (MVA85A) is a viral vector
vaccine produced to prevent tuberculosis.
Objectives
To assess and summarize the effects of the MVA85A vaccine boosting BCG in humans.
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register; Central Register of Controlled Trials (CENTRAL); MED-
LINE (PubMed); Embase (Ovid); and four other databases. We searched the WHO ICTRP and ClinicalTrials.gov. All searches were
run up to 10 May 2018.
Selection criteria
We evaluated randomized controlled trials of MVA85A vaccine given with BCG in people regardless of age or HIV status.
Data collection and analysis
Two review authors independently assessed the eligibility and risk of bias of trials, and extracted and analyzed data. The primary
outcome was active tuberculosis disease. We summarized dichotomous outcomes using risk ratios (RR) and risk differences (RD), with
95% confidence intervals (CI). Where appropriate, we combined data in meta-analyses. Where meta-analysis was inappropriate, we
summarized results narratively.
1MVA85A vaccine to enhance BCG for preventing tuberculosis (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Main results
The search identified six studies relating to four Phase 2 randomized controlled trials enrolling 3838 participants. Funding was by
government bodies, charities, and philanthropic donors. Five studies included infants, one of them infants born to HIV-positive
mothers. One study included adults living with HIV. All trials included authors from Oxford University who led the laboratory
development of the vaccine. Participants received intradermal MVA85A after BCG in some studies, and before selective deferred BCG
in HIV-exposed infants.
The largest trial in 2797 African children was well conducted with low risk of bias for most parameters. Risk of bias was uncertain for
selective reporting because there were no precise case definition endpoints for active tuberculosis published prior to the trial analysis.
MVA85A added to BCG compared to BCG alone probably has no effect on the risk of developing microbiologically confirmed
tuberculosis (RR 0.97, 95% CI 0.58 to 1.62; 3439 participants, 2 trials; moderate-certainty evidence), or the risk of starting on
tuberculosis treatment (RR 1.10, 95% CI 0.92 to 1.33; 3687 participants, 3 trials; moderate-certainty evidence). MVA85A probably
has no effect on the risk of developing latent tuberculosis (RR 1.01, 95% CI 0.85 to 1.21; 3831 participants, 4 trials; moderate-
certainty evidence). Vaccinating people with MVA85A in addition to BCG did not cause life-threatening serious adverse effects (RD
0.00, 95% CI -0.00 to 0.00; 3692 participants, 3 trials; high-certainty evidence). Vaccination with MVA85A is probably associated
with an increased risk of local skin adverse effects (3187 participants, 3 trials; moderate-certainty evidence), but not systemic adverse
effect related to vaccination (144 participants, 1 trial; low-certainty evidence). This safety profile is consistent with Phase 1 studies
which outlined a transient, superficial reaction local to the injection site and mild short-lived symptoms such as malaise and fever.
Authors’ conclusions
MVA85A delivered by intradermal injection in addition to BCG is safe but not effective in reducing the risk of developing tuberculosis.
P L A I N L A N G U A G E S U M M A R Y
MVA85A vaccine as a booster to BCG for prevention of tuberculosis
What is the aim of this review?
The aim of this Cochrane review was to evaluate the effectiveness and safety of using MVA85A in addition to BCG compared to using
BCG alone for prevention of tuberculosis.
Key messages
MVA85A in addition to BCG showed no added benefit to BCG in prevention of acquiring tuberculosis.
What was studied in the review?
Tuberculosis is an infectious airborne disease which affects the lungs and other organs in the body. It can either be active when a person
shows signs and symptoms or has confirmatory tests for tuberculosis or latent when a person has inhaled the bacteria before but does
not show signs and symptoms of sickness. Currently, there is only one vaccine licensed for prevention of this disease, which is called
BCG. However, the ability for the BCG vaccine to prevent tuberculosis differs in different settings and patient groups resulting in
tuberculosis still remaining a problem worldwide despite children being immunized. MVA85A is a vaccine that was investigated for
prevention of tuberculosis with the hope that when used in addition to BCG it will improve prevention of people getting tuberculosis.
What are the main results of this review?
After examining the research published up to 10 May 2018, we included six study findings from four randomized controlled trials
(clinical trials where people are randomly put into one of two or more treatment groups), enrolling 3838 children and adults. Based on
these studies of mostly children and adults living in Africa, MVA85A added to BCG compared to BCG alone probably has no effect on
the risk of developing active tuberculosis defined as microbiologically confirmed tuberculosis (moderate-certainty evidence) or the risk
of starting on tuberculosis treatment (moderate-certainty evidence). MVA85A has no effect on the risk of developing latent tuberculosis
(moderate-certainty evidence). MVA85A does not cause any life-threatening serious side effects (highly-certainty evidence). There were
more local skin reactions in people vaccinated with MVA85A, however, there was no increase in overall side effects in people given
MVA85A.
How up-to-date is this review?
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The review authors searched for studies that have been published up to May 2018.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
MVA85A compared to placebo for preventing tuberculosis
Patient or population: HIV-posit ive and -negat ive adults and children
Setting: South Af rica, Senegal
Intervention: MVA85A
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with MVA85A
Active tuberculosis:
confirmed by culture
or Xpert® MTB/RIF
longest reported fol-
low-up
17 per 1000 16 per 1000
(10 to 28)
RR 0.97
(0.58 to 1.62)
3439
(2 RCTs)
⊕⊕⊕©
Moderatea,b,c
Vaccinat ing peo-
ple with MVA85A in ad-
dit ion to BCG probably
made lit t le or no dif fer-
ence to the risk of devel-
oping act ive tuberculo-
sis
Active tuberculosis:
started on tuberculosis
treatment
102 per 1000 112 per 1000
(94 to 136)
RR 1.10
(0.92 to 1.33)
3687
(3 RCTs)
⊕⊕⊕©
Moderatea,c,d
Vaccinat ing
people with MVA85A in
addit ion to BCG prob-
ably made lit t le or no
dif ference to the risk of
needing to start tuber-
culosis treatment
Latent tuberculosis 114 per 1000 115 per 1000
(97 to 138)
RR 1.01
(0.85 to 1.21)
3831
(4 RCTs)
⊕⊕⊕©
Moderatec,d,e
Vaccinat ing
people with MVA85A in
addit ion to BCG prob-
ably made lit t le or no
dif ference to the risk of
developing latent tuber-
culosis
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Serious adverse ef-
fects
1 per 1000 1 per 1000
(0 to 4)
RD 0.00
(-0.00 to 0.00)f
3692
(3 RCTs)
⊕⊕⊕⊕
High
Vaccinat ing
people with MVA85A
in addit ion to BCG did
not cause lif e-threaten-
ing serious adverse ef -
fects
Adverse effects of any
severity (local reac-
tions of the skin)
Vaccinat ion with MVA85A was associated with
more react ions at the site of the inject ion.g
- 3187
(3 RCTs)
⊕⊕⊕©
Moderateh,i,j
Vaccinat ing
people with MVA85A in
addit ion to BCG proba-
bly increased the risk of
having an adverse reac-
t ion related to vaccina-
t ion at the site of the
inject ion
Adverse effects of
any severity (systemic
symptoms)
Adverse events reported included malaise,
lethargy, fever,and vomit ing although dif ferences
between groups were not signif icant at a 95% CI
level.g
- 144
(1 RCT)
⊕⊕©©
Lowk,l,m
Vaccinat ing peo-
ple with MVA85A in ad-
dit ion to BCG may not
have been associated
with an increase in ad-
verse ef fects related to
vaccinat ion
Adverse events of any
severity
808 per 1000 849 per 1000
(824 to 873)
RR 1.05
(1.02 to 1.08)
3836
(4 RCTs)
⊕⊕⊕⊕
Highn
Vac-
cinat ion with MVA85A
alone slight ly increased
the risk of having an ad-
verse event
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
BCG: Bacillus Calmette-Guérin; CI: conf idence interval; RCT: randomized controlled trial; RD: risk dif f erence; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
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Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aNot downgraded for risk of bias. The largest trial was at unclear risk of bias due to select ive report ing; however, the outcomes
presented were unlikely to be af fected by this (Tameris 2013).
bDowngraded by one level for imprecision. Few events and wide CIs containing clinically appreciable benef it and harm.
cNot downgraded for indirectness. The only trial in HIV-posit ive adults was stopped early meaning it was underpowered to
detect ef f icacy (Ndiaye 2015). Therefore, evidence of ef f icacy is more generalizable to infants; however, results in adults
were consistent with lit t le or no ef fect being seen across all endpoints.
dDowngraded by one level for imprecision. Broad CI containing lit t le or no ef fect and clinically appreciable harm.
eNot downgraded for risk of bias. The largest trial was at unclear risk of bias due to select ive report ing; however, the outcome
of latent tuberculosis was unlikely to be af fected by this (Tameris 2013).
fRisk dif ference presented as explained in our result sect ion.
gExtensive invest igat ion of the vaccine in Phase 1 studies out lined in the Background of this review outlined ‘‘a transient,
superf icial react ion local to the inject ion site and mild short-lived viral symptoms’’ consistent with the f indings reported in the
Phase 2 trials.
hDowngraded by one level for imprecision. Broad CIs containing clinically appreciable benef it and harm.
iNot downgraded for risk of bias. The largest study reported local adverse events and def ined these as solicited by the
vaccine (Tameris 2013).
jNot downgraded for heterogeneity. While there might be some heterogeneity between the included trials in terms of t ime of
outcome collect ion, the outcomes are consistent in favour to placebo as shown in Analysis 1.5.
kDowngraded by one level for risk of bias. There were some def iciencies in the trial report ing these outcomes.
lAddit ional safety data f rom Phase 1 studies in 712 part icipants did not show any adverse ef fect signals (see sect ion in
Background of this review).
mDowngraded by one level for imprecision. Few events reported in the largest trial (Tameris 2013), data not disaggregated in
the second largest trial (Ndiaye 2015).
nNot downgraded for inconsistency. I2 value of 37% judged to be non-signif icant heterogeneity.
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B A C K G R O U N D
Description of the condition
Tuberculosis is an infectious disease caused by Mycobacterium tu-
berculosis. It was estimated that 10 million people developed tu-
berculosis in 2017. Tuberculosis now ranks first, followed by HIV,
as the leading cause of death from an infectious disease world-
wide killing an estimated 1.6 million people in 2017, including
300,000 people living with HIV. Over 95% of these people were
living in low- and middle-income countries (WHO 2018).
Tuberculosis can be classed as active when people experience signs
or symptoms of tuberculosis or have radiological evidence of it.
Tuberculosis can also be classified as latent tuberculosis infection
(LTBI) where immunological evidence of previous exposure to M
tuberculosis exists without clinical or radiological evidence of the
disease (CDC 2000). Of healthy adults with immunological evi-
dence of previous exposure to M tuberculosis, the overall lifetime
risk of progressing to active disease if not treated for the infection
is 5% to 10% (Harries 2006). Often this happens months or years
after the initial infection in response to a weakening of the body’s
immune system. The probability of developing active disease is
higher in HIV-positive people, people with diabetes, and young
children (Baker 2011; Perez-Velez 2012; Tiemersma 2011). Fifty
percent of infants with evidence of LTBI will progress to active
disease if untreated (Marais 2004). People with LTBI require early
diagnosis and treatment to reduce the pool of active tuberculosis
cases. This is particularly important in high-risk groups, such as
those coinfected with HIV (Sharma 2012). Tuberculosis can be
treated with long courses of multiple antibiotics, but the rise of
HIV and spread of multidrug-resistant tuberculosis (MDR-TB)
means that tuberculosis is still one of the largest threats to pub-
lic health worldwide (WHO 2018). Structural determinants such
as rapid urbanization of populations and economic inequalities,
social determinants such as poverty and poor housing, alongside
biological factors such as HIV and drug-resistant strains of tuber-
culosis play a vital role in the spread of tuberculosis through vul-
nerable populations (Daftary 2012).
The Bacillus Calmette-Guérin (BCG) vaccine is currently the only
available vaccine. Epidemiological studies indicate that it has a
protective effect against tuberculosis disease in children, particu-
larly against the more severe forms of the disease such as tubercu-
losis meningitis or miliary tuberculosis (Roy 2014). The effective-
ness of BCG differs greatly depending on the site of infection. It
has consistent protection against tuberculous meningitis and mil-
iary disease in children but variable protection against pulmonary
tuberculosis (Abubakar 2013; Colditz 1995). As a result, despite
many areas achieving high coverage of BCG vaccination, the dis-
ease remains a problem, and a new tuberculosis vaccine remains
an important global research priority (WHO 2018).
Previously it has been impossible to ascertain reliably whether the
BCG vaccine protected against active disease or infection with M
tuberculosis. This was due to the tuberculin skin test being unable
to distinguish between cases of LTBI and people who had been
vaccinated with BCG (Roy 2014). Therefore, the development
and use of interferon γ release assays (IGRA), which can distin-
guish between tuberculosis infection and vaccination, has proved
useful. This has allowed researchers to establish that BCG vaccina-
tion reduces the risk of Mycobacterium infection in some settings
(Eisenhut 2009).
Description of the intervention
Many researchers and policymakers emphasize that a new effective
vaccine could be a major contribution to tuberculosis control and
elimination as a public health problem (de Cassan 2010). There
are 12 vaccine candidates in clinical trials: eight in Phase 2 or Phase
3, and four in Phase 1. They include candidates to prevent the
development of tuberculosis, and candidates to help improve the
outcomes of treatment for tuberculosis disease (WHO 2018).
The modified Vaccinia Ankara virus-expressing antigen 85A
(MVA85A) is a viral vector vaccine based on the modified Vac-
cinia Ankara (MVA) virus. MVA is an attenuated virus that does
not replicate in human tissue and, as such, has been used as a
platform to encode multiple antigens and allowing development
of multivalent vaccines (Altenburg 2014). In this case, MVA has
had pieces of DNA from M tuberculosis inserted into it, so that
it expresses the antigen 85A. This antigen complex is an enzyme
that is involved in the cell wall biosynthesis of M tuberculosis and
constitutes a vital part of the way in which the bacteria forms its
outer mycomembrane. This is important for the viability of the
mycobacterium and works as an effective barrier to drug therapies
by repelling some antibiotics and preventing them from entering
the cell (Favrot 2013).
Immunological studies have shown that a prime boost strategy,
where MVA85A is used to boost the effects of BCG, is effective in
expanding immune responses specific to M tuberculosis (Beveridge
2007). Thus,MVA85Awas proposed primarily as a booster to peo-
ple already vaccinated with BCG (Tameris 2013). Further studies
have assessed MVA85A in other regimens including in combina-
tion with other viral vector vaccines (Sheehan 2015).
How the intervention might work
MVA85A is the first vaccine since 1968 to be tested in efficacy trials
(Tameris 2013). It has been tried with a promise of prolonged an-
timycobacterial immunity in human UK trials (McShane 2004),
and in tuberculosis endemic areas (Hawkridge 2008). The inten-
tion is that MVA85A would boost the immune response to tu-
berculosis above that which is afforded by vaccination with BCG
(Roy 2014). MVA85A is administered as a single intradermal dose
in people who have already received BCG vaccine (Tameris 2013).
Other routes have been studied in animal studies, such as intra-
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venous administration (Romano 2006), and are being considered
in humans (Satti 2014).
The researchers who developed the vaccine evaluated its effects
in animals and conducted Phase 1 studies in humans. Early lit-
erature and reviews by the team noted the vaccine was safe and
produced an immune response in several populations (McShane
2004; Rowland 2012).
One independent systematic review of the animal studies, car-
ried out by some members of this Cochrane Review team, raised
questions about whether these animal studies provided evidence
of efficacy in the various animal models used (Kashangura 2015),
when clinical and pathological endpoints were examined in a va-
riety of animal models subjected to challenge studies. This has led
to a debate about the reporting of animal studies, in particular
the lack of published protocols so that the question being tack-
led in an animal study is made clear in advance (Cohen 2018).
These studies administered BCG, BCG and MVA85A, or no vac-
cine. Afterwards, animals were exposed to tuberculosis challenge.
Clearly progression to clinical trial is not solely based on evidence
derived from preclinical efficacy studies, and MVA85A was evalu-
ated in a number of trials in humans before proceeding to an effi-
cacy study (McShane 2018). However, preclinical studies remain
an important component of the tuberculosis vaccine development
paradigm (Barker 2012; McShane 2014).
The systematic review of animal studies pointed out that there was
one study in macaques where more monkeys required euthanasia
in the MVA85A plus BCG vaccine group than the BCG control
group (Kashangura 2015). This led to considerable controversy
as to whether the publication of the results were delayed (Cohen
2018). The findings from this study could be the result of chance;
or because the vaccine impaired functional immunity; or the re-
sult of a separate adverse effect. The vaccine development team
then carried out a relatively large number of safety studies in hu-
mans; and, in their words, “none of the 14 trials of MVA85A in
over 400 humans (the target species) before the infant efficacy trial
showed a safety signal” (McShane 2018). The standard approach
for Cochrane Reviews within the Cochrane Infectious Diseases
Group is to only summarize efficacy trials. However, as the pri-
mary concern of the studies included in this review was safety, we
summarized the considerable number of Phase 1 studies that the
researchers carried out to exclude severe adverse effects attributable
to the vaccine in humans in this ’Background’ section of the re-
view. We searched registered clinical trial databases (ClinicalTri-
als.gov, World Health Organization (WHO) International Clini-
cal Trials Registry Platform (ICTRP), Pan African Trials Registry,
EU Clinical Trials Register) in June 2017 and summarized the
Phase 1 studies identified in Table 1.We found 21 separate studies
as registered (prospectively and retrospectively) dating from 2003
with the most recent studies scheduled to complete follow-up in
2018. In addition, we found an existing narrative review of Phase
1 studies (Rowland 2012), which summarized Phase 1 safety data
relating to selected trials including unpublished data and com-
pared this to selected trials in yellow fever and BCG.
The 21 studies included 712 participants investigated from 2002
with follow-up expected to be completed by 2018. The studies
covered a diverse population in the UK, South Africa, Senegal,
and The Gambia with HIV-positive and HIV-negative people as
well as infants, children, and adults. Intramuscular, intradermal,
and aerosolized delivery routes were all investigated. The summary
showedmost of the adverse effects related to vaccination weremild
and were contained locally to the injection site. There were very
few serious adverse effects; erythema and mild pain were the most
common adverse effects of the vaccine.
Why it is important to do this review
Summarizing the evidence to date will be useful to the pub-
lic, scientists, and to others interested in innovation in tuber-
culosis as a case study from laboratory development to field
testing. If critical appraisal and systematic review of this vac-
cine in humans shows no clear effect, this raises questions about
any further testing. However, as of November 2017, there were
ongoing studies looking at aerosolized delivery of the vaccine
(NCT01954563; NCT02532036). In 2017, studies were pub-
lished that addressed the immunogenicity of the candidate tu-
berculosis vaccine MVA85A in Schistosomiasis-infected teenagers
(Wajja 2017), and a further efficacy study in HIV-exposed infants
(Nemes 2018).
O B J E C T I V E S
To assess and summarize the effects of theMVA85A vaccine boost-
ing BCG in humans.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs) that include measures of
clinical efficacy (Phase 2 clinical trials).
Types of participants
Any person regardless of age or HIV status.
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Types of interventions
Intervention
MVA85A vaccine regardless of vaccination schedule, dosage,
route, or formulation given with BCG.
Control
BCG alone, or Candin® (Candida albicans skin test antigen).
Types of outcome measures
Primary outcomes
• Active tuberculosis, defined by:
◦ clinical signs and symptoms plus confirmation by
microscopy, culture, or Xpert® MTB/RIF (an automated
nucleic-acid amplification test);
◦ treatment commenced for tuberculosis.
Secondary outcomes
• Latent tuberculosis, diagnosed by IGRA or Mantoux
without clinical or radiological evidence of active disease.
Adverse outcomes
• Adverse effects of any severity, defined as “an adverse event
for which the causal relation between the intervention and the
event is at least a reasonable possibility” (Loke 2011).
• Serious adverse effects, defined as an adverse event
attributable to the intervention “leading to death, are life
threatening, requires inpatient hospitalisation or prolongation of
existing hospitalisation, or result in persistent or significant
disability or incapacity” (ICH 1994).
• Adverse events of any severity, defined as “any untoward
medical occurrence that may present during treatment with a
pharmaceutical product but which does not necessarily have a
causal relationship with this treatment” (WHO-ART 2008).
• Abnormal haematological tests during the follow-up period
after being vaccinated.
• Abnormal biochemical tests during the follow-up period
after being vaccinated.
Search methods for identification of studies
We conducted the literature search up to the 10 May 2018 and
identified potential studies regardless of language or publication
status (published, unpublished, in press, and in progress).
Electronic searches
We searched the following databases using the search terms and
strategy described in Appendix 1: the Cochrane Infectious Dis-
eases Group Specialized Register (10 May 2018); the Cochrane
Central Register of Controlled Trials (CENTRAL, 2018, Issue 4,
published in the Cochrane Library); MEDLINE (PubMed, 1966
to 10 May 2018); Embase (Ovid, 1947 to 10 May 2018); Sci-
ence Citation Index-Expanded, Social Sciences Citation index,
conference proceedings (Web of Science, 1900 to 10 May 2018);
and CINAHL (EBSCOHost (1982 to 10 May 2018). We also
searched the World Health Organization (WHO) International
Clinical Trials Registry Platform (ICTRP; www.who.int/ictrp/
en/), and ClinicalTrials.gov (clinicaltrials.gov/ct2/home), for tri-
als in progress, up to 10 May 2018, using MVA85A, “modified
vaccinia virus Ankara”, Ag85A, “Antigen 85A”, and tuberculosis
OR tuberculosis as search terms.
Searching other resources
We searched the proceedings and abstracts of the following tuber-
culosis conferences: Union World Conference on Lung Health,
European Respiratory Society, and the International Conference
of the American Thoracic Society (ATS), from 2012 to 2018. We
also handsearched reference lists of relevant papers.
Data collection and analysis
Selection of studies
Two review authors independently screened all abstracts retrieved
by the search strategy above using predefined eligibility criteria
designed and piloted by the review authors. We excluded clearly
irrelevant studies. We searched for multiple publications using
studies from the same data set. We retrieved full-text copies for all
trials thought to be potentially relevant. Two review authors (SoJ
and SaJ) independently assessed all identified trials for inclusion
in the review using the predefined inclusion criteria.
We resolved any disagreements in assessment through discussion.
In cases of unresolved differences, a third review author adjudi-
cated. We kept records of the initial results and the changes after
discussion. We also kept a list all studies excluded after full-text
assessment in the Characteristics of excluded studies table. We il-
lustrated the study selection process in a PRISMA diagram (Figure
1).
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Figure 1. Study flow diagram.
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Data extraction and management
We designed and piloted data extraction forms. Two review au-
thors independently performed data extraction. We gathered in-
formation from each included trial separately on trial characteris-
tics. These included:
• study setting, design, study duration, population sample
size, and power calculations;
• baseline characteristics of study population including age,
sex, weight, prematurity, HIV, other comorbidity, whether
breastfeeding, race, HIV status, antiretroviral therapy (ART),
CD4 count, and viral load;
• intervention and control group vaccine dosages, routes of
administration, and times of vaccination;
• time of outcome measure after administering MVA85A;
• duration of follow-up, withdrawals from the study, and
reasons for withdrawal.
All outcomes were dichotomous, so we tabulated the numbers of
participants who developed tuberculosis or an adverse event (n)
with the total sample size number (N) in each comparison group.
We documented the different definitions of outcomes in the trials
for further consideration and only combined data from endpoints
that were similar across studies.
Assessment of risk of bias in included studies
We assessed risk of bias for RCTs using the Cochrane ’Risk of bias’
tool (Higgins 2011). Two review authors independently assessed
studies for risk of bias. We resolved any disagreement through
discussion and, where necessary, through consultation with a third
review author.
We assessed sequence generation (if predictable method used) and
allocation concealment for selection bias and detection bias by
looking at blinding methods. We also considered both the inten-
tion of blinding and the success of blinding for each outcome. If
there was no description of the procedure, for example how ran-
domization was done, we marked it as unclear.
In addition, we examined the objectivity of outcomemeasures, use
of intention-to-treat (ITT) analysis, loss to follow-up, and selective
outcome reporting to assess the risk of bias in included studies.
We assessed whether outcome measures were specified a priori and
whether the published endpoints matched those specified in study
protocols.
We assessed incomplete outcome data in each included trial to de-
termine the proportion of missing results and whether it affected
the results in terms of event risk and effect size. We assessed if
reasons for missing data were related to adverse events or death
from MVA85A and if missing data were balanced in the two ex-
perimental groups to have an overall decision on risk associated
with incomplete outcome data.
We assessed other dimensions to risk of bias, including conflicts
of interest, large differences in baseline characteristics, and early
cessation of the trial.
We assessed the included trials for risk of bias of adverse events
by examining if monitoring was active or passive; whether par-
ticipants and outcome assessors were blinded; whether the out-
come data reporting was complete; whether all participants were
included; and whether data analysis was independent of pharma-
ceutical companies (Table 2; Bukirwa 2014).We also looked at the
times when data were collected in comparison to when they were
reported. All this information was included under overall study
assessment of blinding, selective outcome reporting, incomplete
outcome data, or other biases.
Measures of treatment effect
We analysed all data using Review Manager 5 (Review Manager
2014). We pooled dichotomous data using risk ratios (RR) with
their corresponding 95% confidence intervals (CI). When inap-
propriate due to a small number of events in each group, we pre-
sented the pooled data using risk difference (RD) with their 95%
CI.
Unit of analysis issues
For included studies that had multiple intervention arms, we in-
cluded data from these studies by splitting the control group so
that participants were only included in the meta-analysis once.
Dealing with missing data
In our protocol, we anticipated that if the amount of incomplete
outcome data was such that the trials were thought to be at a high
risk of bias, we may have used imputation and perform sensitivity
analyses to investigate the impact of these missing data. However,
we identified no studies where missing data affected our ability to
measure outcomes. Therefore, we used available-case analysis, as
planned in our protocol.
Assessment of heterogeneity
We assessed extracted data from included trials to find key differ-
ences in population groups, study setting, intervention and con-
trol groups, dosages and route of vaccine administration, or timing
between BCG and boosting. We assessed degree of risk of bias,
when and how the outcome was measured, and variation in treat-
ment effects.
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Wedetermined the level of heterogeneity by inspecting forest plots
for overlapping CIs.We judged a Chi2 P value significance level of
0.1 or less as likely heterogeneity. An I2 statistic value of less than
40% was regarded as not showing any significant heterogeneity.
Assessment of reporting biases
There was an insufficient number of trials included and so we were
unable to assess for publication bias using funnel plots or Egger
regression.
Data synthesis
We used the fixed-effect Mantel-Haenszel model for meta-analy-
sis where there was little heterogeneity. The intention for meta-
analysis of adverse outcomes was limited to three to five of the
most frequent adverse effects and all those that were considered
to be serious. However, due to different methods of monitoring
adverse effects that in turn lead to different results where meta-
analysis could not be performed, we gave a narrative report.
Subgroup analysis and investigation of heterogeneity
We intended to explore heterogeneity by: subgroup by children
and adults; background prevalence of tuberculosis (or tuberculosis
incidence in the control group); HIV status; and geographical
location. However, there were not enough trials to explore such
subgroups when we found high heterogeneity.
We considered random-effects meta-analysis if subgroup analysis
did not explain the heterogeneity. We applied the I2 statistic ac-
cording to guidance of: less than 40% as not significant hetero-
geneity; 30% to 60% representing moderate heterogeneity; 50%
to 90% representing substantial heterogeneity; and 75% to 100%
considerable heterogeneity (Higgins 2011). We regarded a Chi2 P
value significance level of 0.1 or less and an I2 statistic greater than
40% as showing significant heterogeneity, in which case we either
considered a random-effects model or did not performmeta-anal-
ysis.
Sensitivity analysis
We did not perform sensitivity analysis for imputed data, risk of
bias, or any other peculiarities between the trials identified during
the review process.
Certainty of the evidence
We assessed the certainty of the evidence using the GRADE ap-
proach (Schünemann 2013). We constructed a ’Summary of find-
ings’ table, which outlines the main review findings alongside the
certainty of the evidence.
R E S U L T S
Description of studies
Results of the search
We identified 153 records, with 152 records remaining after re-
moving duplicates. We excluded 118 records based on title and
abstract and assessed the full text of 34 articles. We excluded 28
full-text articles. Six articles fulfilled the eligibility criteria andwere
included in the review. See Figure 1 for the flow diagram of inclu-
sion and exclusion of studies in the review.
Included studies
Six studies (3838 participants) that met our inclusion criteria re-
ported findings from four Phase 2 clinical trials (Ndiaye 2015;
Nemes 2018; Scriba 2011; Tameris 2013). Andrews 2017 and
Bunyasi 2017 presented data based on the Tameris 2013 clinical
trial. The six included studies are described in the Characteristics
of included studies table.
Setting and time
All took place in South Africa involving rural and urban areas
between 2008 and 2015, with one trial that took place at two sites:
South Africa and Senegal (Ndiaye 2015).
Source of funding
Aeras sponsored five trials (Andrews 2017; Bunyasi 2017; Ndiaye
2015; Nemes 2018; Tameris 2013). The University of Oxford
sponsored one trial (Scriba 2011). The Wellcome Trust funded
all the trials. Other funders were Oxford Emergent Tuberculo-
sis Consortium (OETC) for Ndiaye 2015 and Tameris 2013, the
European and Developing Countries Clinical Trials Partnership
and the Bill and Melinda Gates Foundation for Ndiaye 2015, the
UK Medical Research Council for Nemes 2018, and the Euro-
peAID European Commission for Scriba 2011. Andrews 2017
and Bunyasi 2017 conducted further follow-up based on the par-
ticipants enrolled in Tameris 2013, and mentioned that there was
no specific additional funding for the analysis performed.
Participants
Five trials included infants (Andrews 2017; Bunyasi 2017; Nemes
2018; Scriba 2011; Tameris 2013). One trial assessed the effi-
cacy and safety of the vaccine in adults with HIV (Ndiaye 2015).
Tameris 2013 and Scriba 2011 recruited infants who were HIV-
negative, while Nemes 2018 assessed the vaccine in newborns of
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HIV-positive mothers. None of the trials reported other morbidi-
ties. In Tameris 2013, 412 (29.4%) participants in the interven-
tion group and 268 (26.4%) participants in the control group
were preterm.
Interventions
Intervention
All the infants in the intervention groups received a single dose
of intradermal MVA85A. In the trial recruiting adults, the 324
adults allocated in the intervention group received a second dose
(booster) of intradermal vaccine six months after the first dose
(Ndiaye 2015). The vaccine was given at a dose of 1 × 108 plaque-
forming units (pfu) in Ndiaye 2015, Nemes 2018, and Tameris
2013. Scriba 2011 assessed three different doses of the vaccine by
giving a dose of 2.5x107 pfu, 5x107 pfu and 1x 108 pfu to 36
participants in each of the three groups. All the infants in Scriba
2011 and Tameris 2013 received the BCG vaccine in the first
four weeks of life, prior to receiving the MVA85A vaccine, as an
inclusion criteria. Nemes 2018 gave the MVA85A vaccine to the
neonates in the first 96 hours of life, with no prior administration
of BCG, and gave BCG at eight weeks of age only toHIV-negative
infants. Ndiaye 2015 did not mention whether the adults they
recruited received BCG.
Comparator
Five trials gave Candida skin test antigen (Candin®) as a placebo,
using the same route (intradermal) and schedule (one or two doses)
as for the intervention group in each of the trial (Andrews 2017;
Bunyasi 2017; Ndiaye 2015; Nemes 2018; Tameris 2013). Scriba
2011 gave the infants in the comparator group one dose of pneu-
mococcal 7-valent conjugate vaccine by the intramuscular route.
Outcomes
Three studies reported different endpoints as measures of tuber-
culosis disease (Ndiaye 2015; Nemes 2018; Tameris 2013). These
are compared in Table 3.
All the included studies reported data on latent tuberculosis (or
tuberculosis infection) to assess either efficacy or safety outcomes.
Four trials looked at safety outcomes, including adverse effects
of any severity, serious adverse effects, and adverse events of any
severity (Ndiaye 2015; Nemes 2018; Scriba 2011; Tameris 2013).
Tameris 2013 collected data on biochemical or haematological
blood test findings but did not report this element of their primary
outcome. Ndiaye 2015 collected data on blood tests but did not
report disaggregated findings. Only Scriba 2011 and Nemes 2018
reported on blood test data collected.
Length and method of follow-up
Scriba 2011 followed up participants for 24 weeks, Nemes 2018
for 52 weeks, Ndiaye 2015 for at least six months after the last
participant was enrolled, and Tameris 2013 for up to 39 months.
Andrews 2017 was an observational follow-up study of the par-
ticipants enrolled in Tameris 2013; authors analysed the data col-
lected at day 336 after the intervention and at the end of the study,
which ranged from six to 24 months after day 336. Bunyasi 2017
followed the participants recruited in Tameris 2013 for a median
of five years.
Investigators of five studies used diary cards to record adverse
events during the sevendays following vaccination (Andrews 2017;
Bunyasi 2017; Ndiaye 2015; Scriba 2011; Tameris 2013); Nemes
2018 did not mention this. Researchers performed blood inves-
tigations at several intervals in all trials, to detect adverse events
and to assess immunogenicity. Ndiaye 2015 and Tameris 2013
performed active follow-up every three months to identify signs,
symptoms, or exposure to tuberculosis that merited further inves-
tigation, while this was done at irregular but planned intervals in
Scriba 2011 andNemes 2018. The long-term follow-up study was
based on passive surveillance based on the electronic tuberculosis
register database (Bunyasi 2017).
Excluded studies
We excluded 28 studies from the review, with the reasons for ex-
clusion listed in the Characteristics of excluded studies table.
Studies awaiting classification
We did not identify any studies that are awaiting classification.
Ongoing studies
We did not identify any ongoing studies.
Risk of bias in included studies
See Characteristics of included studies table for the assessment of
the risk of bias for each included study. See Figure 2 and Figure 3
for the risk of bias summaries.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Five trials were at low risk of selection bias (Andrews 2017; Bunyasi
2017; Ndiaye 2015; Nemes 2018; Tameris 2013). They reported
adequate sequence generation and methods of allocation conceal-
ment. Scriba 2011 used systematic allocation at a 3:1 ratio allow-
ing predictability of the sequence (high risk of bias).
Blinding
Three studies had adequate blinding of participants, study person-
nel, laboratory assessors, and clinical assessors and were at low risk
for performance and detection bias in all domains (Ndiaye 2015;
Nemes 2018; Tameris 2013). Five studies reported blinding of
participants and study personnel (Andrews 2017; Bunyasi 2017;
Ndiaye 2015; Nemes 2018; Tameris 2013). Scriba 2011, an open-
label trial with different routes of administration for placebo and
vaccine, had low risk of detection bias for laboratory assessors as
outcomes were objective and high risk of detection bias for sub-
jective assessments by clinicians. Two studies were at unclear risk
of detection bias for laboratory assessors and clinicians (Andrews
2017; Bunyasi 2017). Andrews 2017 did not provide any details
on blinding, while Bunyasi 2017 reported on post-trial data and
had no information on how data was collected from registers.
Incomplete outcome data
Four trials reported details of all randomized participants (Ndiaye
2015; Nemes 2018; Scriba 2011; Tameris 2013). Only a few par-
ticipants randomized were not included in the analysis, without
resulting in a disbalance between the intervention and control
groups. Indeed, three participants were randomized in the control
group in Tameris 2013, but not included in the efficacy analysis
(two of themwere not included either in the safety analysis), while
five participants were randomized (four in the intervention group
and one in the control group), but not included in the efficacy
analysis in Ndiaye 2015. As a result we considered these studies
at low risk of attrition bias. There were no details of how many of
each group came from the 119 participants excluded fromTameris
2013 for analysis in Bunyasi 2017. Andrews 2017 and Bunyasi
2017 had an unclear risk of attrition bias as these were follow-up
studies from Tameris 2013, and there were unclear discrepancies
with those reported previously.
Selective reporting
Nemes 2018 was prospectively registered and appeared free of se-
lective outcome reporting as ascertained from data in trial registers
and reports of trials. We also judged Scriba 2011 at low risk of
reporting bias, with all the outcomes reported in their methods
section presented in the results.
Four studies were at unclear risk of bias due to selective reporting (
Andrews 2017; Bunyasi 2017;Ndiaye 2015;Tameris 2013). There
were multiple instances where predefined endpoints were poorly
defined or were deviated from in the final reported results as laid
out in Table 4.
Description of Tameris 2013 published prior to commencement
of the trial (NCT00953927) stated that the authors intended to
report endpoints of clinical disease based on “observational cohort
studies.” This was subsequently changed following the publica-
tion of the trial in October 2013 to include “clinically-derived
tuberculosis diagnostic criteria.” The main trial reports adapting
the primary elements proposed in a consensus statement (Graham
2012). There was no record of the change in approach from em-
pirically derived endpoints to endpoints developed by the investi-
gators in the study protocol.
Tameris and colleagues reported on three outcomes with complex
definitions (Table 3).
• Endpoint one, described as “primary efficacy endpoint,”
comprising nine criteria, which included a binary measure of
quantiFERON conversion.
• Endpoint two, described as “exploratory efficacy endpoint,”
comprising nine criteria.
• Endpoint three, described as “exploratory efficacy
endpoint,” which was defined as “all participants placed on
treatment for tuberculosis.”
The difference between endpoints one and two, which varied in
the direction of the point estimate of the effect, was 5 mm on
a tuberculin skin test or household contact with acid-fast bacilli
(AFB) smear-positive person (Table 3). The process of defining
these three endpoints was unexplained, and it is unclear why these
specific definitions were used. These endpoint definitions were
only used in this trial and not in subsequent studies.
In a subsequent critique, Behr and colleagues noted that the out-
comes reported in the trial did not include the simple measure of
a positive microbiological endpoint (Behr 2013). The endpoint
used in the abstract was endpoint one, which authors have settled
as primary efficacy outcome, while endpoints two and three were
reported as exploratory outcomes. The complexity of the defini-
tions and the analysis in Behr’s paper pointed to the risk of se-
lective reporting. This may not have been intentional, but arose
with post-hoc approaches with different approaches to expressing
the results, but could be excluded if outcomes were precisely and
clearly defined a priori. The only information publicly available
prior to the trial commencing were broad descriptions of the out-
come. Hence for selective reporting the classification was unclear.
Andrews 2017 was at unclear risk of reporting bias as this was
a nested observational study and there was no prespecified study
protocol. Ndiaye 2015 was at unclear risk of reporting bias as
the authors commented that there were no differences between
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biological and haematological tests; however, no data or how these
data were analysed to come to this conclusion were reported.
Other potential sources of bias
We considered that the risk of other potential biases was unclear in
all included studies.Wewere concerned as a number of the authors
were involved in the private company manufacturing the vaccine
or were patent holders for MVA85A. In these circumstances, it
would be good practice for this to be declared in the publication.
Only one study declared no conflicts in relation to patent holding
(Scriba 2011).
Two trials reported a role of funders in design, data analysis,
and manuscript writing (Ndiaye 2015; Tameris 2013), and one
study had employees of the funder involved in manuscript writ-
ing (Andrews 2017).Ndiaye 2015 calculated incident tuberculosis
cases from day 28 after vaccination versus from day 0 in Tameris
2013. This was likely to be due to the risk of pre-existing undi-
agnosed tuberculosis being inappropriately counted as developing
following the intervention. If participants are not followed from
the start of the intervention then a period of follow-up has been
excluded, and participants who experienced the outcome soon af-
ter intervention will be missing from analyses. We considered this
to be of unclear risk of bias as it is unclear if this impacted on
outcomes.
Adverse events
For adverse events, we conducted additional assessments on ad-
equacy of safety monitoring and completeness of reporting for
participant-reported outcomes and laboratory tests taken (Table
5). Four trials reported on safety outcomes (Ndiaye 2015; Nemes
2018; Scriba 2011; Tameris 2013). Monitoring of participant-re-
ported outcomes was active in all trials and blinding was adequate
in two trials (Nemes 2018; Tameris 2013). All trials reported spec-
ified timing of data collection but only one study reported under
some of the days (Scriba 2011). None of the trials completely re-
ported outcomes on prespecified time points including for labo-
ratory results. All trials reported all participants who received in-
tervention per-protocol. Timing of taking laboratory tests was in-
adequate in Scriba 2011 and Tameris 2013 as there was no clear
indication of tests being taken at the end of the study.
Effects of interventions
See: Summary of findings for the main comparison MVA85A
compared to placebo for preventing tuberculosis
See Summary of findings for the main comparison.
Active tuberculosis
Studies varies in the way they defined active tuberculosis (see sec-
tion “description of studies” (Table 3)). Tameris 2013 and Ndiaye
2015 reported hierarchical endpoints including microbiologically
confirmed tuberculosis, composite clinical definitions, and partic-
ipants starting on tuberculosis treatment, with no significant ef-
fect consistently seen across endpoints (Analysis 2.1; Analysis 2.2;
Table 3; Table 6).
Tameris 2013 reported three endpoints in their main manuscript,
with endpoint one described as their primary efficacy end-
point (RR 0.82, 95% CI 0.52 to 1.30, point estimate favour-
ing MVA85A). A fourth endpoint was described in the supple-
mentary material, taking into account the microbiologically con-
firmed cases of tuberculosis. Other outcomes (endpoint two, end-
point three, and endpoint four of microbiologically confirmed
cases) were not statistically different, although their point estimate
favoured placebo (endpoint two: RR 1.05, 95% CI 0.73 to 1.53;
endpoint 3: RR 1.10, 95%CI 0.91 to 1.33; endpoint four (micro-
biologically confirmed): RR 1.10, 95% CI 0.60 to 2.00; Analysis
2.1; Figure 4).
Figure 4. Forest plot of comparison: 2 Comparison of endpoints, outcome: 2.1 Tameris 2013: incidence of
tuberculosis according to post-hoc endpoints.
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Two studies reported no effect of MVA85A on cases of active
tuberculosis confirmed by culture or Xpert®MTB/RIF (RR 0.97,
95% CI 0.58 to 1.62; 3439 participants, two trials) (Analysis 1.1;
Figure 5; Ndiaye 2015; Tameris 2013).
Figure 5. Forest plot of comparison: 1 MVA85A Vs Placebo, outcome: 1.1 Tuberculosis confirmed by
culture or Xpert® MTB/RIF longest reported follow-up.
Three studies (Ndiaye 2015;Nemes2018;Tameris 2013) reported
no effect of MVA85A on cases of active tuberculosis when consid-
ering patients started on tuberculosis treatment (RR 1.10, 95%
CI 0.92 to 1.33; 3687 participants, 3 trials; Analysis 1.2; Figure
6).
Figure 6. Forest plot of comparison: 1 MVA85A versus placebo, outcome: 1.2 Active tuberculosis: started
on tuberculosis treatment.
Nemes 2018 reported active tuberculosis as defined by participants
starting tuberculosis treatment. One participant in this trial was
diagnosed by culture; however, the authors did not report what
intervention this participant received.
Latent tuberculosis
Four studies reported no effect of MVA85A on cases of latent
tuberculosis (RR 1.01, 95% CI 0.85 to 1.21; 3831 participants,
four trials; Analysis 1.3).
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Scriba 2011 was underpowered and not designed to detect mea-
sures of efficacy. However, they reported latent tuberculosis, pre-
sumably as a measure of safety, as this outcome was poorly defined
a priori.
Adverse effects
Four studies reported effects of any severity (Table 7). We pre-
sented the effect of the estimates for adverse effects of any severity
with disaggregated (Analysis 1.4; Figure 7) and aggregated data
(Analysis 1.5) to provide detailed information as provided by the
study authors. However, we did not perform meta-analysis of the
estimates due to high heterogeneity. Local reactions of the skin at
the injection site was the most common adverse effect associated
with the vaccine MVA85A, this was reported in three studies, with
the three studies showing direction towards more adverse effects
in the intervention group (3187 participants; Nemes 2018; Scriba
2011; Tameris 2013). However, only one study reported systemic
symptoms defined as fever, lethargy, malaise, and vomiting (144
participants; Scriba 2011). Therefore, we chose to report adverse
effects of any severity disaggregated by local reactions of the skin
and systemic symptoms in our Summary of findings for the main
comparison as different amount of information is provided for
each group (Scriba 2011).
Figure 7. Forest plot of comparison: 1 MVA85A versus placebo, outcome: 1.4 Adverse effects of any severity.
Three studies reported no increase in the risk of experiencing a
serious adverse effect attributable to MVA85A (3692 participants;
Analysis 1.6). Nemes 2018 reported serious adverse events and
specified that none of them were related to the investigational
product. Therefore, we classified this as no serious adverse effects
following the definition of our review.
Adverse events of any severity
Four studies reported a small increase in the risk of experiencing an
adverse event of any severity following vaccination with MVA85A
(RR 1.05, 95% CI 1.02 to 1.08; 3836 participants; Analysis 1.7;
Table 8). Adverse effects related to the vaccine and adverse events
not attributed to the vaccine were conflated in the largest trial. No
disaggregated data were available.
Abnormal haematological and biochemical tests
Three studies reported abnormal haematological or biochemical
laboratory tests. The percentage of those with elevated liver en-
zymes ranged from 2.8% to 25% in the three different groups
reported in Scriba 2011 and there was a dose-response effect of
MVA85A. However, none of the doses showed a significant in-
crease at a 95% CI. Ndiaye 2015 reported that routine haemato-
logical and biochemical test results did not differ between study
groups but disaggregated data were not reported. Nemes 2018 re-
ported no difference between groups in the percentage of people
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with abnormal biochemical tests (11.4% versus 10.4%), but dis-
aggregated data were not reported. The largest study performed
haematological and biochemical tests but did not report data
(Tameris 2013). We summarized the report and findings of ab-
normal haematological and biochemical tests in Table 9, and pre-
sented the effect of estimate for abnormal biochemical tests only
(Analysis 1.8), as only one study reported disaggregated data for
abnormal haematological tests.
D I S C U S S I O N
Summary of main results
Vaccinating people with MVA85A in addition to BCG:
• probably makes little or no difference to the risk of
developing active tuberculosis (moderate-certainty evidence);
• probably makes little or no difference to the risk of needing
to start tuberculosis treatment (moderate-certainty evidence);
• probably does not have an important effect on the risk of
developing latent tuberculosis (moderate-certainty evidence);
• does not cause life-threatening serious adverse effects (high-
certainty evidence);
• probably increases the risk of having an adverse reaction
related to vaccination at the site of the injection (moderate-
certainty evidence);
• may not be associated with an increase in systemic adverse
effects related to vaccination (low-certainty evidence).
Vaccination withMVA85A alone slightly increases the risk of hav-
ing an adverse event (high-certainty evidence).
Overall completeness and applicability of
evidence
This review included trials from two countries in Africa. No stud-
ies that measured efficacy of the MVA85A vaccine have been car-
ried out elsewhere. The review included studies on HIV-positive
adults,HIV-negative infants, and infants exposed toHIV. It would
be reasonable to generalize the results of these findings to other
populations of HIV-negative infants. The early cessation of the
only trial in HIV-positive adults, resulting in reduced follow-up
from two years to minimum six months and a reduction of study
sample size from 1200 to 625, led this study to be underpowered
for evaluation of efficacy (Ndiaye 2015). This may have limited
the certainty of any inferences made to adults with HIV at high
risk of contracting tuberculosis in terms of efficacy of MVA85A
in this population. The effect of tuberculosis vaccination would
be very similar regardless of geographical variation. Data from this
review consistently showed no effect of the vaccine. As such, it is
reasonable to generalize these findings to broader populations. For
safety outcomes, the Phase 1 studies that we summarized in the
Background section and Table 1, included adults, children, and
infants from the UK and three African countries. Most of the ad-
verse effects related to vaccination were mild and were contained
locally to the injection site. This supports the trial findings sum-
marized in this review.
Certainty of the evidence
Overall the included studies were well-conducted. For most of our
outcomes, there were few events and broad CIs for the pooled
estimates of effect which contained clinically appreciable benefit
and harm or no effect (see Summary of findings for the main
comparison).
In the largest trial, the main reported endpoint (endpoint one)
point estimate was in the direction of benefit of the vaccine on
tuberculosis disease (Analysis 2.1; Tameris 2013). Whether this
was due to the definition of endpoints or due to statistical het-
erogeneity was unclear. To minimize the impact of this inconsis-
tency we presented results for cases diagnosed microbiologically
and cases defined by being started on treatment. This was felt to
reflect the most specific measure of efficacy and a measure of the
real-world situation. As a result of this, the methodological uncer-
tainties surrounding case definition did not reduce our confidence
in the effect estimates.
Failure to follow-up participants from the start of intervention for
efficacy measures in Ndiaye 2015 risked biasing outcomes. While
it is plausible that participants with undiagnosed active tubercu-
losis would be inappropriately picked up, it is also plausible that
participants who hypothetically could have developed tuberculo-
sis immediately after vaccination would be excluded from analy-
sis. However, the potential impact of this was unclear and as such
we did not downgrade due to risk of bias for efficacy outcomes
including this study.
In terms of latent tuberculosis, using the online calculator at
www.sealedenvelope.com/power/binary-noninferior/ at a signifi-
cance level of 5% and with 80% power at a failure rate of 11% and
a non-inferiority limit of 5% a sample size per group of 484 would
be sufficient to demonstrate non-inferiority. Therefore, in terms of
risk of developing latent tuberculosis where we had high certainty
evidence that MVA85A had no important effect in reducing risk,
we are confident that future trials are unlikely to change this re-
sult as we had 3831 participants in the analysis versus a minimum
number of 484 participants required in each group.
Regarding the safety outcomes, the summary of findings from the
Phase I trials for MVA85A performed in adults, adolescents, and
infants with 712 participants showed that most of the adverse
effects related to vaccination were mild and were contained locally
to the injection site, andnone of the trials reported a serious adverse
event attributable to the vaccine. This supports the certainty of
the evidence found in this review.
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Potential biases in the review process
We followed standard methods in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011). The Cochrane In-
fectious Disease Group Information Specialist performed a com-
prehensive literature searchwith no restriction in language to iden-
tify all eligible studies, thus it is unlikely that we missed any large
studies.We were unable to formally assess publication bias as fewer
than 10 studies met our inclusion criteria.
Agreements and disagreements with other
studies or reviews
No previous systematic reviews have been undertaken looking at
the effects of MVA85A.
There has beenmuch debate over the contribution of animal stud-
ies to the progression of MVA85A vaccine to trial (Cohen 2018;
McShane 2018). We systematically assessed Phase 1 and 2 data
and we found no difference in tuberculosis incidence in any pop-
ulation, and no increase in the risk of serious adverse effects at-
tributable to the vaccine. There was a small increase in the risk of
experiencing any adverse event.
The findings of this review are consistent in that MVA85A is not
efficacious for preventing tuberculosis and that there is no evidence
that theMVA85A vaccine caused any serious harm to participants
in the trials during its investigation.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
MVA85A in conjunction with Bacillus Calmette-Guérin (BCG)
has no effect on the risk of developing active or latent tuberculosis.
Implications for research
Researchers should define outcomes precisely before starting the
trial. If composite outcomes are developed during the trial, this
process needs to be transparent, clearly reported, and published
prior to breaking the randomized code. Standardization of out-
come measures for tuberculosis vaccine efficacy maymake it easier
for future researchers in the field and allow easy comparison and
meta-analysis of different study outcomes.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Andrews 2017
Methods Study objective: to investigate the relation between QFT conversion interferon-γ values
and risk of subsequent active TB disease and of QFT reversion
This is a follow-up study of the Tameris 2013 trial.
Study design: observational follow-up study based on a parallel-group, randomized,
placebo-controlled double-blind Phase 2b trial
Study duration: 41 months
Length of follow-up: ≥ 15 months after enrolment, and up to 41 months (based on the
Tameris 2013 trial)
Follow-up method: no additional data for this study than described in the Tameris 2013
trial.
Losses to follow-up: 285/2797 children from Tameris 2013 to enrolment for this study
analysis at day 336; 467/2512 children from day 336 until the end of the study
Power calculation: not relevant for this observational follow-up study
Participants Number: 2512/2797 participants enrolled in Tameris 2013 were quantiFERON-nega-
tive at enrolment and had another quantiFERON done at day 336 and were therefore
enrolled for this study analysis. No disaggregated data on age and sex between interven-
tion and control groups among these 2512 participants
Target group: infants aged 4-6 months
Inclusion criteria
• Healthy infants aged 4-6 months
• Received BCG vaccination within 7 days of birth
• Received all age-appropriate routine immunizations, and 2 doses of
pneumococcal conjugate vaccine at least 28 days before study vaccination (amended to
14 days during enrolment)
• HIV ELISA-negative
• QuantiFERON-negative
• No substantial exposure to a person with known TB
• Written informed consent obtained from parents/guardian
• Weight: by chart > 3rd percentile on study day 0 or, if < 3rd percentile, infant had
stable growth pattern
• Ability to complete follow-up period as required by the protocol
• Completed simultaneous enrolment in the Aeras Vaccine Development Registry
protocol
Exclusion criteria
• Acute illness on study day 0
• Fever ≥ 37.5 °C on study day 0
• Evidence of significant active infection on study day 0
• Received a EPI immunization within 14 days prior to study day 0
• Historical or virological evidence of individual or maternal HIV-1 infection
• History of allergic disease or reactions likely to be exacerbated by any component
of the
study vaccine
• Previous medical history, or evidence, of an intercurrent illness that may
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Andrews 2017 (Continued)
compromise the
safety of the infant in the study
• Evidence of chronic hepatitis from any cause
• History or evidence of any systemic disease on physical examination or any acute,
chronic
or intercurrent illness that, in the opinion of the investigator, may have interfered with
the
evaluation of the safety or immunogenicity of the vaccine
• History of or known TB or treatment for TB
• Shared residence since birth with a person with active TB or on ATT for < 2
months
HIV status: negative
Other comorbidities: none reported
Preterms:
• Intervention group: 412 (29.4%)
• Control group: 368 (26.4%)
Interventions Intervention group
• Vaccine: MVA85A/AERAS-485
• Dosage: 1 × 108 pfu in 0.06 mL
• Route: intradermal
• Schedule: at day 1, 1 dose
• Timing after BCG: inclusion criteria request BCG given during the first 7 days of
life.
Control group
• Vaccine: Candida skin test antigen (Candin, AllerMed, USA)
• Dosage: 0.06 mL
• Route: intradermal
• Schedule: at day 1, 1 dose
• Timing after BCG: inclusion criteria request BCG given during the first 7 days of
life.
Outcomes Outcomes included in this review
• Active TB
Outcomes not included in this review:
• QFT converters
Notes Country: South Africa
Setting: rural, near Cape Town
Background prevalence of TB: extremely high. The overall incidence of TB in South
Africa in 2011 was estimated to be almost 1%, and the incidence of TB in children aged
< 2 years was about 3% at the trial site
Study dates: enrolment 15 July 2009 to 4 May 2011 and follow-up until 60 days after
the 25 October 2012
Study sponsor: Aeras
Other funders: Wellcome Trust and Oxford Emergent TB Consortium (OETC). No
additional funding than from the Tameris 2013 trial was obtained for the analysis of
these data.
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Andrews 2017 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote from report: “Young children were
randomly assigned (1:1) using indepen-
dently generated sequences with block sizes
of four to receive one dose of the vaccine
MVA85A or Candida spp skin test antigen
(placebo control).”
Comment: an independent statistician pre-
pared the randomization schedule as re-
ported in the trial where the data came from
that is referenced above (Tameris 2013).
Allocation concealment (selection bias) Low risk Comment: voice response system ade-
quately concealed allocation of interven-
tion as reported in Tameris 2013.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: same as in Tameris 2013. It did
not affect long-term follow-up.
Quote fromTameris 2013: “Parents or legal
guardians of study participants, study staff
administering vaccine or undertaking fol-
low up clinical assessments and laboratory
staff were masked to intervention group as-
signment.”
“Doses were prepared and labelled in
masked syringes by an unmasked study
pharmacist.”
Blinding of outcome assessment (detection
bias): laboratory assessors
Unclear risk Comment: no information onwhether lab-
oratory assessors were blinded
Blinding of outcome assessment (detection
bias): clinical assessors
All outcomes
Unclear risk Quote from report: “Study clinicians were
not masked to QFT values, but strict case
definitions were used that excluded QFT
results.”
Comment: although clinicians were not
masked to QFT values, relevant outcome
of conversion is objective and authors used
strict case definitions. May not necessarily
affect incidence in the two groups as there
were no QFT differences between placebo
and MVA85A at 336 days (baseline). No
details on whether they were masked to
group (MVA85A or placebo)
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote from report: “Among the 2797
young children enrolled in the MVA85A
trial (Tameris 2013) 2772 (99%) young
children had a negative QFT at enrolment,
five (<1%) had no quantitative results avail-
able, and 20 (1%) had an indeterminate
result. 1399 young children were allocated
to MVA85A and 1398 were allocated to
placebo. Among those 2772 young chil-
dren with a negative QFT at baseline, 2512
(91%) had aQFTdone at the day 336 visit.
”
Comment: no imputation
Of above 2512, 172 positive and 13 inde-
terminate. Numbers of negative and con-
verted did not add up to the initial study
group
Selective reporting (reporting bias) Unclear risk Comment: outcome/objective of this study
not seen in protocol for trial (MVA85A 020
TRIAL). Could not find separate protocol
for Andrews trial
Other bias Unclear risk Comment: employees and beneficiaries of
funders were involved in design, analysis,
and manuscript writing. This study was a
follow-up of children enrolled in Tameris
2013 trial.
Bunyasi 2017
Methods Study objective: to evaluate the long-term effectiveness of infant MVA85A vaccination
against TB
This is a long-term follow-up study of the Tameris 2013 trial.
Study design: retrospective passive follow-up of the randomized controlled trial
Study duration: 22 months for enrolment in the original trial
Length of follow-up: median of 5 years’ follow-up
Follow-up method: passive surveillance based on the electronic TB register database
Losses to follow-up: there was some inconsistency between the number of participants
included for this long-term follow-up study and the number of participants who were
lost to follow-up at an early point in the original trial (Tameris 2013).
Power calculation: not relevant for this observational follow-up study
Participants Number: 2794 in the Tameris 2013 trial, 2678 included in this long-term follow-up
analysis
Median age: 4.8 years (IQR 4.4 to 5.2) at the end of the extended follow-up period,
comparable across intervention and control groups with no detailed data given in the
manuscript
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Target group: infants aged 4-6 months
Inclusion criteria for the base trial
• Healthy infants aged 4-6 months
• Received BCG vaccination within 7 days of birth
• Received all age-appropriate routine immunizations, and 2 doses of
pneumococcal conjugate vaccine at least 28 days before study vaccination (amended to
14 days during enrolment)
• HIV ELISA-negative
• QuantiFERON-negative
• No substantial exposure to a person with known TB
• Written informed consent obtained from parents/guardian
• Weight: by chart > 3rd percentile on study day 0 or, if < 3rd percentile, infant has
shown
a stable growth pattern
• Ability to complete follow-up period as required by the protocol
• Completed simultaneous enrolment in the Aeras Vaccine Development Registry
protocol
Exclusion criteria for the base trial
• Acute illness on study day 0
• Fever ≥ 37.5 °C on study day 0
• Evidence of significant active infection on study day 0
• Received a EPI immunization within 14 days prior to study day 0
• Historical or virological evidence of individual or maternal HIV-1 infection
• History of allergic disease or reactions likely to be exacerbated by any component
of the
study vaccine
• Previous medical history, or evidence, of an intercurrent illness that may
compromise the
safety of the infant in the study
• Evidence of chronic hepatitis from any cause
• History or evidence of any systemic disease on physical examination or any acute,
chronic
or intercurrent illness that, in the opinion of the investigator, may interfere with the
evaluation of the safety or immunogenicity of the vaccine
• History of or known TB or treatment for TB
• Shared residence since birth with a person with active TB or on ATT for < 2
months
HIV status: negative
Other comorbidities: none reported
Preterms in the initial sample size of the base trial
• Intervention group: 412 (29.4%)
• Control group: 368 (26.4%)
Interventions Intervention group
• Vaccine: MVA85A/AERAS-485
• Dosage: 1 × 108 pfu in 0.06 mL
• Route: intradermal
• Schedule: at day 1, 1 dose
• Timing after BCG: inclusion criteria request BCG given during the first 7 days of
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life.
Control group
• Vaccine: Candida skin test antigen (Candin, AllerMed, USA)
• Dosage: 0.06 mL
• Route: intradermal
• Schedule: at day 1, 1 dose
• Timing after BCG: inclusion criteria request BCG given during the first 7 days of
life.
Outcomes Outcomes included in this review
• Active TB. Definition used was the endpoint 3 described in Tameris 2013:
participants placed on treatment for TB by a health professional.
• Latent TB, defined by a positive quantiFERON or a positive TST
Outcomes not included in this review
• Subgroup analysis of active TB and latent TB in children who received and did
not receive isoniazid prophylaxis.
Notes Country: South Africa
Setting: rural, near Cape Town
Background prevalence of TB: extremely high. The overall incidence of TB in South
Africa in 2011 was estimated to be almost 1%, and the incidence of TB in children aged
< 2 years was about 3% at the trial site
Study dates: enrolment from 15 July 2009 to 4 May 2011 and follow-up to 2014
Study sponsor: Aeras
Other funders: Wellcome trust and Oxford Emergent TB Consortium (OETC). No
additional funding than from the Tameris 2013 trial was obtained for the analysis of
these data.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote from Tameris 2013: ”We randomly
allocated infants in a 1.1 ratio with a block
size of 4 using interactive voice /online re-
sponse system…“
”An independent statistician prepared the
randomisation schedule.“
Allocation concealment (selection bias) Low risk Comment: voice response system ade-
quately concealed allocation of interven-
tion as reported in Tameris 2013.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: same as in Tameris 2013. It did
not affect long term follow-up.
Quote fromTameris 2013: ”Parents or legal
guardians of study participants, study staff
administering vaccine or undertaking fol-
low-up clinical assessments and laboratory
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staff were masked to intervention group as-
signment.“
”Doses were prepared and labelled in
masked syringes by an unmasked study
pharmacists.“
Blinding of outcome assessment (detection
bias): laboratory assessors
Unclear risk Not applicable.
Blinding of outcome assessment (detection
bias): clinical assessors
All outcomes
Unclear risk Quote from report: ”We also obtainedpost-
trial data from a regional electronic TB reg-
ister (ETR) (2012-2014)
Comment: no information on how data
were collected from this register. Clinical
diagnosis of TB was also a subjective out-
come
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote from report: “199 participants dis-
continued FU [follow-up] early.”
Comment: 119 participants were excluded
from Tameris 2013 for analysis in the cur-
rent study. No details on how many partic-
ipants there were from each group of the
study
Selective reporting (reporting bias) Unclear risk Comment: raw data not reported. Only
reported incidence rate ratios. There were
no disaggregated data on missing data for
each group. Number of participants with
TB were not reported per group. Only in-
cidence per year
Other bias Unclear risk Quote from report: “The authors received
no specific funding for this work,” “Con-
flicts of interest: none declared.” “Study
is a follow up to Tameris 2013 where
the trial sponsor contributed to study de-
sign, data interpretation, and writing of the
manuscript.”
33MVA85A vaccine to enhance BCG for preventing tuberculosis (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Ndiaye 2015
Methods Study objective: to assess the safety, immunogenicity, and efficacy of MVA85A vaccine
in adults HIV-positive
Study design: multicentre randomized double-blind placebo-controlled trial, Phase 2
Study duration: 46 months (from August 2011 to May 2014)
Length of follow-up: ≥ 6 months after enrolment
Follow-up method
• Diary card to report adverse events during the 7 days following vaccination.
• Direct questionnaire to enquire about adverse events on days 7 and 28 after
vaccination.
• Blood tests for routine haematological and biochemical analysis, and for
peripheral CD4 cell count and HIV-1 viral load at screening, before booster
vaccination, and on days 7 and 28 after vaccination.
• Blood test for peripheral CD4 cell count and HIV-1 viral load every 3 months
until 6 months after booster vaccination.
• Active follow-up every 3 months until the last participant enrolled had completed
6 months of follow-up after the booster vaccination.
Losses to follow-up: 14 participants. 5/324 (1.5%) in the intervention group and 9/326
(2.7%) in the control group. Additionally, 3 participants in the intervention group and 2
in the control group withdrew consent; and 2 participants in the intervention group and
4 in the control group died before the end of the study. In total, 325/649 participants
completed the study
Power calculation: the sample size calculation was planned to detect active TB. However,
after the Tameris 2013 efficacy data were revised, the authors changed the trial design
with safety as the primary objective. A smaller sample size was considered and follow-
up was shortened. Therefore, the present trial was underpowered to detect an effect on
active TB
Participants Number: 649 (292 from Cape Town, 358 from Dakar).
• Intervention group (324 participants): median age: 38.0 years (range: 21 to 49
years); 18.2% men
• Control group (325 participants): median age: 39.0 years (range: 22 to 41 years);
22% men
Target group: adults
Inclusion criteria
• Completed written informed consent process prior to undergoing any screening
evaluations.
• Men or women aged ≥ 18 and ≤ 50 years on study day 0
• In general good health, confirmed by medical history and physical examination
• Had ability to complete follow-up period as required by the protocol
• Had laboratory evidence of HIV infection, defined as a positive HIV-1 ELISA
test plus a positive confirmatory test (e.g. a second HIV-1ELISA, PCR, or rapid
ELISA) diagnosed prior to randomization.
• Was willing to allow the investigators to discuss the participant’s medical history
with the participant’s HIV physician.
• If not receiving ART at the time of randomization, must have 2 CD4+
lymphocyte count test results > 350 cells/mm3, performed ≥ 4 weeks apart, 1
performed within 6 months prior to randomization and 1 within 45 days prior to
randomization.
• If receiving ART at the time of randomization, must have 2 CD4+ lymphocyte
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count test results > 300 cells/mm3, performed ≥ 4 weeks apart, 1 performed within 6
months prior to randomization and 1 within 45 days prior to randomization.
Participants on ART must have been receiving ART for ≥ 6 months prior to
randomization and must have an undetectable HIV viral load within 45 days prior to
randomization. Women who received ART as part of the PMTCT program must have
completed therapy ≥ 2 months prior to randomization.
• Had:
◦ a negative QFT test result and tuberculin PPD skin test ≤ 5 mm induration
within 45 days prior to randomization or
◦ a positive QFT test result or tuberculin PPD skin test > 5 mm (or both) and
had completed ≥ 5 months of isoniazid preventive therapy within 3 years prior to
randomization or
◦ a positive QFT test result or tuberculin PPD skin test > 5 mm (or both) and
had completed treatment for TB disease within 3 years prior to randomization.
• Women: ability to avoid pregnancy during the trial. Women physically capable of
pregnancy (not sterilized and still menstruating or within 1 year of the last menses if
menopausal) in sexual relationships with men must have avoided pregnancy by using
an acceptable method of avoiding pregnancy from 28 days prior to administration of
the study vaccine to 6 months after the last study vaccination. Acceptable methods of
avoiding pregnancy included a sterile sexual partner, sexual abstinence (not engaging in
sexual intercourse), and any contraceptive method deemed clinically suitable by the
trial clinician taking into account ART status.
• Had completed the written informed consent process for simultaneous enrolment
in Aeras Vaccine Development Registry protocol.
Exclusion criteria
• Acute illness
• Fever (temperature > 37.5 °C)
• Significant symptomatic infection (including laboratory evidence of HIV-2)
• Any evidence of active TB disease, as determined by any clinical, radiological, or
microbiology measurements.
• Any AIDS defining illness by WHO criteria
• Use of any investigational or non-registered drug, vaccine, or medical device other
than the study vaccine within 182 days preceding dosing of study vaccine, or planned
use during the study period
• Previous receipt of a recombinant MVA or FP vector at any time.
• Enrolled in any other clinical product trial
• Administration of methotrexate, azathioprine, cyclophosphamide, oral
corticosteroids (for corticosteroids, this will mean prednisolone, or equivalent, ≥ 0.5
mg/kg/day; inhaled and topical steroids are allowed), and other immunosuppressive
therapies, or blood products or blood derivatives within the 6 months prior to
randomization
• History of allergic disease or reactions likely to be exacerbated by any component
of the vaccine, e.g. egg products
• History of cancer (except basal cell carcinoma of the skin and cervical carcinoma
in situ), or renal failure
• Severe depression, schizophrenia, or mania
• Pregnant, breast-feeding, or both
• History of anaphylaxis in reaction to vaccination
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• Principal investigator assessment of lack of willingness to participate and comply
with all requirements of the protocol, or identification of any factor felt to significantly
increase the participant’s risk of experiencing an adverse outcome
HIV status: positive
Other comorbidities: none reported
Preterms: not mentioned
Interventions Intervention group
• Vaccine: MVA85A/AERAS-85
• Dosage: 1 × 108 pfu
• Route: intradermal.
• Schedule: at day 1, and 2nd (booster) dose given 6 months after the 1st injection
• Timing after BCG: not mentioned
Control group
• Vaccine: Candida skin test antigen
• Dosage: not mentioned
• Route: intradermal
• Schedule: at day 1, and 2nd (booster) dose given 6 months after the 1st injection
• Timing after BCG: not mentioned
Outcomes Outcomes included in this review
• Active TB
◦ Endpoint 1: culture or Xpert® MTB/RIF positivity
◦ Endpoint 2: endpoint 1 and a composite clinical endpoint; see detailed
criteria in Table 4
◦ Endpoint 3: participants placed on treatment for TB by a health professional
• Latent TB
• Adverse effects of any severity
• Serious adverse effects
• Adverse events of any severity
Outcomes not included in this review
• Immunogenicity tests
Notes Countries: South Africa and Senegal
Setting: Cape Town (South Africa) and Dakar (Senegal), urban
Background prevalence of TB
• In Cape Town: TB case notification rate was at least 1500 per 100,000
population per year
• In Dakar: TB incidence rate of 0.14% in 2013
Study dates: 4 August 2011 to 24 April 2013 for enrolment, with follow-up until 19
May 2014
Study sponsor: Aeras. Collaborators: University ofOxford andEuropean andDeveloping
Countries Clinical Trials Partnership (EDCTP) (IP.2007.32080.002)
Funders: Bill & Melinda Gates Foundation, Wellcome Trust, and Oxford-Emergent
Tuberculosis Consortium
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote from the report: “Participants were
randomly assigned (1:1) in blocks of four
by a randomly generated sequence of par-
ticipant identification numbers via an in-
teractive voice response system to receive
two intradermal injections of either 1 × 10
8 pfu MVA85A or placebo.”
Allocation concealment (selection bias) Low risk Quote from the report: “A statistician un-
involved with study analyses prepared the
interactive voice response system randomi-
sation schedule.”
Comment: the interactive automated voice
response system would make it impossible
to predict the allocation sequence
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote from the report: “Participants,
nurses (who were involved in assessment
and follow-up) investigators, and labora-
tory staff were masked to group allocation.
”
“Doses of vaccines were prepared and la-
belled in masked syringes.”
Quote from the protocol: “The MVA85A/
AERAS-485 and the placebo will be pack-
aged and labelled to appear indistinguish-
able from each other at the time of injec-
tion. Identical syringes and needles will be
used for preparation and administration of
injections of vaccine/placebo, and labels ac-
companying the syringes of prepared vac-
cine/placebo doses will not indicate which
is in the syringe.”
Blinding of outcome assessment (detection
bias): laboratory assessors
Low risk Comment: as quoted above and outcome
objective
Blinding of outcome assessment (detection
bias): clinical assessors
All outcomes
Low risk Quote from the protocol in supplement:
“The study vaccine manager and the study
monitor will be the only persons unblinded
at the site during the study and must not
reveal individual subject treatment assign-
ments to any other member of the study
team. The study vaccinemanagermust be a
designated study team member who is not
an employee of Aeras and who will have no
other clinical or regulatory responsibilities
associated with the conduct of the study
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during the entire study period. Unblinded
study personnel must not participate in the
evaluation of adverse events.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote from the report: “650 were ran-
domly assigned; 649 were included in the
safety analysis and 645 in the per-protocol
analysis.” Median follow-up for the 320 re-
cipients of MVA85A was 655 days and for
the 325 recipients of placebo was 654 days.
“Other than 4 participants, all participants
were included in the analysis.”
Comment: when authors refer to “per-pro-
tocol analysis,” this is actually regarding the
analysis for the efficacy outcome. Results
for per-protocol analyses were noted to be
not different from the intention-to-treat re-
sults that were not reported
Selective reporting (reporting bias) Unclear risk Quote from the report: “Routine haema-
tological and biochemical test results did
not differ between study groups (data not
shown).”
Adverse effects solicited by the vaccine were
not disaggregated by type of event
Other bias Unclear risk Quote from the report: “The secondary
outcome was the efficacy of MVA85A for
the prevention of active tuberculosis in the
per-protocol population which was deter-
mined by the incidence of active tubercu-
losis meeting the definition of endpoint 1,
calculated as the number of new cases of
active tuberculosis with a date of diagnosis
from 28 days after the first vaccination un-
til the end of the study follow-up (May 19,
2014).”
Comment: the start of the intervention
did not coincide with the start of follow-
up; therefore a period of follow-up was ex-
cluded, and participants who experienced
the outcome soon after intervention were
missing from analyses. As such, the way in
which outcomes were measured may bias
effect estimates
This study was stopped early owing to data
from the Tameris 2013 trial. As such, it
was underpowered to measure efficacy out-
comes
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Quote: “Aeras was the trial sponsor and
contributed to study design and data anal-
ysis.”
Comment: impact of sponsor involvement
in analysis of results unclear
Nemes 2018
Methods Study objective: to assess safety and immunogenicity of MVA85A vaccination in new-
borns of HIV-positive mothers, followed by selective deferred BCG vaccination at 8
weeks for HIV-negative infants
Study design: double-blind, randomized controlled trial
Study duration: not mentioned
Length of follow-up: 52 weeks
Follow-up method
• For safety endpoints: infants were monitored at weeks 1, 4, 6, and 8 after
MVA85A/control vaccination and thereafter, at weeks 9, 12, and 16 (corresponding to
weeks 1, 4, and 8 following delayed BCG vaccination at 8 weeks of age), and at week
52. Method of follow-up not detailed.
• For immunogenicity analyses: blood was collected at weeks 4, 8, 16, and 52
Losses to follow-up: 9 participants (3 in the intervention group, 6 in the control group)
Power calculation: the sample size had 90% probability of detecting a serious adverse
event with a true occurrence rate of 1.5% in infants receiving MVA85A vaccine and
80% power to detect a 15% difference in the rate of non-serious adverse events (20%
compared to 35%) between the 2 study groups (P < 0.05)
Participants Number: 248
• Intervention group (123 participants): mean age: day of birth; 49% boys
• Control group (125 participants): mean age: day of birth; 49% boys
Target group: infants of HIV-positive mothers
Inclusion criteria
• HIV-positive mother receiving either cART, or started on PMTCT prophylaxis
• Maternal antenatal and postnatal written informed consent
• Maternal age ≥ 18 years at the time of informed consent
• Infant age < 96 hours; any sex
• Infant birth and residence in the study area
• Mother contactable and able to attend follow-up visits
Exclusion criteria
• Neonatal Apgar score < 7 at 5 minutes
• Infant birth weight < 2000 g or > 4500 g
• Estimated infant gestational age < 32 weeks
• Neonatal respiratory distress
• History or evidence of infant congenital abnormality, or immunosuppressive
condition, other than HIV infection
• Any maternal or infant condition or systemic illness that in the opinion of the
investigator was likely to affect safety or immunogenicity of study vaccine
• Infant BCG vaccination prior to enrolment
• Residence in a household, or frequent close contact, with an adult diagnosed with
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active TB who has not yet completed TB treatment
• Mother with active TB who has not yet completed TB treatment
• Unknown or negative maternal HIV status
• Intention to leave the study area or unable to attend follow-up visits, or both
HIV status: infants of HIV-positive mothers
• Intervention group
◦ Mother receiving ARTs: 80%
◦ Median maternal CD4 count: 442 cells/mm3 (IQR 306 to 607)
• Control group:
◦ Mother receiving ARTs: 81%
◦ Median maternal CD4 count: 400 cells/mm3 (IQR 262 to 554.5)
Other comorbidities: none reported
Preterms: median gestational age
• Intervention group: 39 weeks (IQR 39 to 40)
• Control group: 40 weeks (IQR 39 to 40)
Interventions Intervention group
• Vaccine: MVA85A
• Dosage: 1 × 108 pfu
• Route: intradermal
• Schedule: 1 dose within 96 hours of birth
• Timing after BCG: BCG 1-4 × 105 cfu was selectively given at 8 weeks of age
only to HIV-negative infants
Control group
• Vaccine: Candida skin test antigen (Candin®)
• Dosage: 1 × 108 pfu
• Route: intradermal
• Schedule: 1 dose within 96 hours of birth
• Timing after BCG: BCG 1-4 × 105 cfu was selectively given at 8 weeks of age
only to HIV-negative infants.
Outcomes Outcomes included in this review:
• Active TB: culture-positive or on clinical/radiological grounds and TB contact
history
• Latent TB: quantiFERON conversion at 1 year
• Adverse effects of any severity
• Serious adverse effects
• Adverse events of any severity
• Abnormal laboratory tests
Outcomes not included in this review
• Immunogenicity tests
Notes Country: South Africa
Setting: urban (Cape Winelands east district and Khayelitsha)
Background prevalence of TB: not mentioned
Study dates: not reported. According to Clinicaltrial.gov, the study started in October
2012, and was completed in October 2015
Study sponsor: Aeras. Other funders: UK Medical Research Council, Department for
International Development, and Wellcome Trust Joint Global Health Trials programme
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and AERAS
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote from supplementary: “Assignment
to study armwas double-blinded and based
on a random number sequence prepared by
an independent statistician.”
Allocation concealment (selection bias) Low risk Quote from supplementary: “The study
pharmacist, the only unblinded member of
the study team, controlled the numbered
sealed envelopes containing randomization
armand sequential 3-digit enrolment num-
ber.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: from the statement that the
pharmacist was the only unblinded mem-
ber in the team we assumed everyone else
was blinded and it was effective
Blinding of outcome assessment (detection
bias): laboratory assessors
Low risk Comment: from the statement that the
pharmacist was the only unblinded mem-
ber in the team we assumed everyone else
was blinded and it was effective
Blinding of outcome assessment (detection
bias): clinical assessors
All outcomes
Low risk Comment: from the statement that the
pharmacist was the only unblinded mem-
ber in the team we assumed everyone else
was blinded and it was effective
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: minimal attrition and balance
between groups; 16 inMVA85A group and
19 in control group as set out in figure 1b
Selective reporting (reporting bias) Low risk Comment: reported everything they set out
in protocol. Additionally reported QFT
conversion and incident TB disease; out-
comes were not specified in protocol but of
importance to mention
Other bias Unclear risk Comment: authors declared no conflict of
interest. 1 author declared that they were
patent holders for MVA85A and were re-
sponsible for its development in Scriba
2011.
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Scriba 2011
Methods Study objective: to assess the safety of and to characterize the T-cell response induced by
3 doses of the candidate vaccine, MVA85A, in BCG-vaccinated infants from a setting
where TB was endemic
Study design: open-label, Phase 2a safety, immunogenicity, and dose-finding study
Study duration: 23 months
Length of follow-up: 168 days (24 weeks)
Follow-up method
• Diary cards the first 7 days for registration of local and systemic adverse effects
• Onsite safety data at 60 minutes and on days 2, 7, 28, 84, and 168
• Blood sample for haematology and biochemistry on days 7 and 84
• Blood sample for immunogenicity on days 0, 7, 28, 84, and 168
Losses to follow-up: none
Power calculation: not mentioned
Participants Number: 144
• Intervention group
• ◦ Vaccine group 1 (36 participants): median age: 270.5 days; 42% male
◦ Vaccine group 2 (36 participants): median age: 278.5 days; 47% male
◦ Vaccine group 3 (36 participants): median age: 188 days; 39% male
• Control group (36 participants): median age: 252 days; 62% male
Target group: infants aged 5-12 months
Inclusion criteria
• Children or infants aged 6 months to 11 years
• Participant’s parent/guardian willing and able to give written informed consent
for participation in the study
• Participant is BCG vaccinated within the first 4 weeks of life
• Informed assent from all children aged ≥ 7 years unless judged incapable of
understanding the basic concepts covered in the informed assent form, and from
children aged < 7 years if judged capable of understanding the basic concepts covered
in the informed assent form
• Healthy
• Clinically acceptable laboratory results from screening visit
• Chest x-ray normal with no evidence of active or past TB
• Participant’s parent/legal guardian willing to allow child to undergo an HIV test
• Parent/guardian and participant able (in the Investigators opinion) and willing to
comply with all study requirements
Exclusion criteria
• Participant Mantoux (> 10 mm) or ELISPOT (> 50 spots/million PBMC)
positive for Mycobacterium tuberculosis (PPD, ESAT-6 or CFP-10, or both)
• HIV-positive
• Any other significant disease or disorder which, in the opinion of the investigator,
may either put the person at risk because of participation in the study, or may influence
the result of the study, or the person’s ability to participate in the study
• Have participated in another research study involving an investigational product
in the past 12 weeks
• Previously enrolled into this study
• Received a live vaccine (e.g. measles) in the previous 4 weeks or due to receive a
live vaccine in the 4 weeks following enrolment
HIV status: negative
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Scriba 2011 (Continued)
Other comorbidities: none reported
Preterms: not mentioned
Interventions Intervention group
• Vaccine: MVA85A (manufactured at Impfstoffwerk Dessau-Tornau; Biologika)
• Dosage:
• ◦ Vaccine group 1: 2.5 × 107 pfu in 35 µL
◦ Vaccine group 2: 5 × 107 pfu in 70 µL
◦ Vaccine group 3: 1 × 108 pfu in 135 µL
• Route: intradermal on deltoid arm
• Schedule: at day 1, 1 dose
• Timing after BCG: inclusion criteria request BCG given during the first 4 weeks
of life.
Control group
• Vaccine: pneumococcal 7 valent conjugate (Prevenar, Wyeth)
• Dosage: not specified
• Route: intramuscular, site of injection not mentioned
• Schedule: at day 1, 1 dose
• Timing after BCG: inclusion criteria request BCG given during the first 4 weeks
of life.
Outcomes Outcomes included in this review
• Latent TB (reported under the safety profile)
• Adverse effects of any severity
• Serious adverse effects
• Adverse events of any severity
• Abnormal biochemical tests
Outcomes not included in this review
• Immunogenicity tests
Notes Country: South Africa
Setting: Cape Town, urban
Background prevalence of TB: extremely high (incidence of 1%)
Study dates: February 2008 to December 2009 (according to data published in clinical-
trial.gov, not mentioned in the paper)
Study sponsor: University of Oxford. Funders: EuropeAIDEuropean commission, Well-
come trust
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote from the report: “The aim was to
enroll 144 infants into 3 consecutive vac-
cine dose groups of 48, who would be sys-
tematically allocated at a 3:1 ratio to receive
either MVA85A (groups 1-3) or placebo.”
Comment: randomization method pre-
dictable.
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Allocation concealment (selection bias) High risk Quote from the report: “…systematically
allocated at a 3:1 ratio…”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote from report: “MVA85A, contract
manufactured at Impfstoffwerk Dessau-
Tornau (Biologika), was administered in-
tradermally over the deltoid region of the
arm contralateral to where BCG was ad-
ministered.” Prevenar was administered in-
tramuscularly
Comment: open label with 2 different
routes of administration. Subjective out-
comes, so could influence participants
when reporting the symptoms
Blinding of outcome assessment (detection
bias): laboratory assessors
Low risk Comment: open label, but with no reper-
cussion on objective laboratory outcomes
Blinding of outcome assessment (detection
bias): clinical assessors
All outcomes
High risk Comment: open label, with high repercus-
sion on subjective clinical outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition
Selective reporting (reporting bias) Low risk Comment: all the outcomes mentioned in
the methods section were reported in the
results
Other bias Unclear risk Quote from report: “…are named inven-
tors on a composition of matter patent for
MVA85A filed by the University of Ox-
ford and are shareholders in a joint venture
formed for the further development of this
vaccine.”
Comment: unknown role of funders in the
elaboration of the study and 2 authors with
potential conflict of interest
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Tameris 2013
Methods Study objective: to assess safety, immunogenicity, and efficacy of MVA85A against TB
and Mycobacterium tuberculosis infection in infants.
Study design: parallel-group, randomized, placebo-controlled double-blind Phase 2b
trial
Study duration: 39 months
Length of follow-up: ≥ 15 months after enrolment, and up to 39 months
Follow-up method
• Follow-up at study day 7, study day 28, study day 84, and every 84 days (i.e.
every 3 months) thereafter until the end of the study.
• Safety diary cards for first 7 days, direct questioning at study days 7 and 28 and
serious adverse events throughout the study.
• Peripheral blood for routine haematological and biochemical tests at screening
and on days 7 and 28 after vaccination in an initial safety cohort.
• QFT testing at screening, day 336, at end of study visit, and for infants admitted
to a dedicated study ward for investigation for TB.
• Active follow-up every 3 months to identify signs, symptoms, or exposure that
merited further investigation.
Losses to follow-up
• Intervention group: 61/1399 (4.4%) participants; 37 (2.6%) withdrew consent
• Control group: 65/1398 (4.6%) participants; 25 (1.8%) withdrew consent
Power calculation: given a TB cumulative incidence of 3% over 18 months in the con-
trol group, 1392 participants per treatment group (2784 participants total) would be
required to demonstrate positive efficacy when the true efficacy of MVA85A/AERAS-
485 was approximately 60%. An estimate of 7.5% of participants lost to follow-up in
each treatment group was assumed over 18 months
Participants Number: 2797
• Intervention group (1399 participants): mean age: 146.6 days; 50.6% boys
• Control group (1395 participants; 1398 randomized): mean age: 145.7; 51.2%
boys
Target group: infants aged 4-6 months
Inclusion criteria
• Healthy infants aged 4-6 months
• Received BCG vaccination within 7 days of birth
• Received all age-appropriate routine immunizations, and 2 doses of
pneumococcal conjugate vaccine ≥ 28 days before study vaccination (amended to 14
days during enrolment)
• HIV ELISA-negative
• QuantiFERON-negative
• No substantial exposure to a person with known TB
• Written informed consent obtained from parents/guardian
• Weight: by chart > 3rd percentile on study day 0 or, if < 3rd percentile, infant
showed
a stable growth pattern
• Ability to complete follow-up period as required by the protocol
• Completed simultaneous enrolment in the Aeras Vaccine Development Registry
protocol
Exclusion criteria
• Acute illness on study day 0
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Tameris 2013 (Continued)
• Fever ≥ 37.5 °C on study day 0
• Evidence of significant active infection on study day 0
• Received a EPI immunization within 14 days prior to study day 0
• Historical or virological evidence of individual or maternal HIV-1 infection
• History of allergic disease or reactions likely to be exacerbated by any component
of the
study vaccine
• Previous medical history, or evidence, of an intercurrent illness that may
compromise the
safety of the infant in the study
• Evidence of chronic hepatitis from any cause
• History or evidence of any systemic disease on physical examination or any acute,
chronic,
or intercurrent illness that, in the opinion of the investigator, may have interfered with
the
evaluation of the safety or immunogenicity of the vaccine
• History of or known TB or treatment for TB
• Shared residence since birth with a person with active TB or on ATT for < 2
months
HIV status: negative
Other comorbidities: none reported
Preterms
• Intervention group: 412 (29.4%) participants
• Control group: 368 (26.4%) participants
Interventions Intervention group
• Vaccine: MVA85A/AERAS-485
• Dosage: 1 × 108 pfu in 0.06 mL
• Route: intradermal
• Schedule: at day 1, 1 dose
• Timing after BCG: inclusion criteria request BCG given during the first 7 days of
life.
Control group
• Vaccine: Candida skin test antigen (Candin, AllerMed, USA)
• Dosage: 0.06 mL
• Route: intradermal
• Schedule: at day 1, 1 dose
• Timing after BCG: inclusion criteria request BCG given during the first 7 days of
life.
Outcomes Outcomes included in this review
• Active TB
◦ Endpoint 1: see detailed criteria in Table 2
◦ Endpoint 2: participants diagnosed with TB based on the presence of
specific clinical, radiological, and microbiological findings.
◦ Endpoint 3: participants placed on treatment for TB by a health professional
• Latent TB
• Adverse effects of any severity
• Serious adverse effects
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Tameris 2013 (Continued)
• Adverse events of any severity
Outcomes not included in this review
• Immunogenicity tests
Notes Country: South Africa
Setting: rural, near Cape Town
Background prevalence of TB: extremely high. The overall incidence of TB in South
Africa in 2011 was estimated to be almost 1%, and the incidence of TB in children aged
< 2 years was about 3% at the trial site
Study dates: enrolment 15 July 2009 to 4 May 2011 and follow-up to 25 October 2012
Study sponsor: Aeras. Collaborators: University of Oxford and University of Cape Town.
Funders: Aeras, Wellcome trust and Oxford Emergent tb consortium (OETC)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote from the report: “We randomly al-
located infants in a 1.1 ratio with a block
size of 4 using interactive voice /online re-
sponse system.”
“An independent statistician prepared the
randomisation schedule.”
Allocation concealment (selection bias) Low risk Comment: voice response system ade-
quately concealed allocation of interven-
tion
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote from the report: “Parents or legal
guardians of study participants, study staff
administering vaccine or undertaking fol-
low up clinical assessments and laboratory
staff were masked to intervention group as-
signment.”
“Doses were prepared and labelled in
masked syringes by an unmasked study
pharmacist.”
Comment: syringes had equal amount of
placebo and control.
Quote from the protocol: “packaged and
labelled to appear indistinguishable to each
other.”
Blinding of outcome assessment (detection
bias): laboratory assessors
Low risk Comment: laboratory staff were masked to
intervention group assignment
Blinding of outcome assessment (detection
bias): clinical assessors
All outcomes
Low risk Comment: staff undertaking clinical assess-
ments were masked to intervention group
assignment
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote from the report: “The number
of participants discontinuing the study
did not differ between the two treatment
groups.” 1126 infants (5%) were lost to fol-
low-up, 11 died (< 1%), and 62 (2%) had
consent withdrawn
Comment: reasons for missing outcome
data balanced between the 2 groups and
proportion of missing data not enough to
have a clinically relevant impact on the
intervention effect estimate. Per-protocol
analysis was done and only 1 person was
excluded from analysis from the placebo
group due to dose deviation
Selective reporting (reporting bias) Unclear risk Quote from study description from clin-
ical trials.gov: “Adverse events and clini-
cally relevant laboratory results for the sa-
fety cohort will be summarized to examine
the relationship between treatment group
and key safety endpoints including number
(percentage) of solicited and spontaneous
adverse events, rates of reactogenicity, and
number (percentage) of subjectswith newly
abnormal post-vaccination laboratory val-
ues based on predefined neonatal toxicity
criteria.”
Comment: data were collected; however,
no summary provided on biochemical or
haematological adverse effects
Unclear if endpoints were specified a priori
as endpoint definition was only published
alongside the trial and approach outlined a
priori on clinical trial registry was amended
The differences between endpoint point 1
and 2were 5mmonTST; 2 positive smears
compared to 1 positive smear and residence
in household with positive AFB member.
These endpoints were significantly differ-
ent from the endpoints used in 2 other tri-
als that included efficacy measures (Ndiaye
2015; Nemes 2018).
Other bias Unclear risk Quote from the report: “Aeras was the trial
sponsor. Aeras and the Oxford-Emergent
Tuberculosis Consortium (OETC) con-
tributed to study design, data interpreta-
tion, and writing of the manuscript.”
Comment: impact of sponsor involvement
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on study findings unclear
AFB: acid-fast bacilli; ART: antiretroviral therapy; ATT: antituberculosis therapy; BCG: Bacillus Calmette-Guérin; cART: combination
antiretroviral therapy; CFP-10: culture filtrate protein-10; cfu: colony-forming unit; ELISA: enzyme-linked immunosorbent assay;
ELISPOT: enzyme-linked immune absorbent spot; EPI: Expanded Programme on Immunization; ESAT-6: early secretory antigenic-
6; FP: floating point; IQR: interquartile range; MVA: modified Vaccinia Ankara; PBMC: peripheral blood mononuclear cell; PCR:
polymerase chain reaction; pfu: plaque-forming unit; PMTCT: prevention of mother-to-child transmission; PPD: purified protein
derivative; QFT: QuantiFERON-TB Gold In-Tube; SD: standard deviation; TB: tuberculosis; TST: tuberculin skin test; WHO:
World Health Organization.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Brookes 2008 Different study design
Bunyasi 2015 Different outcomes measured
Dieye 2013 Different study design
Harris 2011 Different study design
Harris 2014a Different study design
Hawkridge 2008 Different study design
Matsumiya 2014a Different outcomes measured
Matsumiya 2014b Different outcomes measured
Matsumiya 2014c Different outcomes measured
McShane 2004 Different study design
Meyer 2013 Different study design
Minassian 2011 Different study design
Minhinnick 2016 Different study design
Mulenga 2015 Different intervention
Odutola 2012 Different study design
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Ota 2011 Different study design
Pathan 2007 Different study design
Pathan 2012 Different study design
Rowland 2012 Different study design
Rowland 2013 Different study design
Sander 2009 Different study design
Satti 2014 Different study design
Scriba 2010 Different study design
Scriba 2012 Different study design
Sheehan 2015 Different study design
Tameris 2014 Measured different outcomes
Tanner 2014 Different study design
Whelan 2009 Different study design
50MVA85A vaccine to enhance BCG for preventing tuberculosis (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
D A T A A N D A N A L Y S E S
Comparison 1. MVA85A versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Active tuberculosis (TB):
confirmed by culture or
Xpert® MTB/RIF longest
reported follow-up
2 3439 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.58, 1.62]
2 Active TB: started on TB
treatment
3 3687 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.92, 1.33]
3 Latent TB 4 3831 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.85, 1.21]
4 Adverse effects of any severity 3 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Local: skin 3 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Malaise 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Lethargy 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 Any fever 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 Vomiting 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Adverse effects of any severity:
aggregated
4 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Serious adverse effects 3 3692 Risk Difference (M-H, Fixed, 95% CI) 0.00 [-0.00, 0.00]
7 Adverse events of any severity 4 3836 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [1.02, 1.08]
8 Abnormal biochemical tests 2 392 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.60, 1.97]
Comparison 2. Comparison of endpoints
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Tameris 2013: incidence of
tuberculosis (TB) according to
post-hoc endpoints
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Ndiaye 2015: incidence of TB
according to post hoc defined
endpoints
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 MVA85A versus placebo, Outcome 1 Active tuberculosis (TB): confirmed by
culture or Xpert® MTB/RIF longest reported follow-up.
Review: MVA85A vaccine to enhance BCG for preventing tuberculosis
Comparison: 1 MVA85A versus placebo
Outcome: 1 Active tuberculosis (TB): confirmed by culture or Xpert MTB/RIF longest reported follow-up
Study or subgroup MVA85A Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ndiaye 2015 (1) 6/320 9/325 30.8 % 0.68 [ 0.24, 1.88 ]
Tameris 2013 (2) 22/1399 20/1395 69.2 % 1.10 [ 0.60, 2.00 ]
Total (95% CI) 1719 1720 100.0 % 0.97 [ 0.58, 1.62 ]
Total events: 28 (MVA85A), 29 (Placebo)
Heterogeneity: Chi2 = 0.64, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours MVA85A Favours placebo
(1) At least 6 months’ follow-up
(2) At least 15 months’ follow-up
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Analysis 1.2. Comparison 1 MVA85A versus placebo, Outcome 2 Active TB: started on TB treatment.
Review: MVA85A vaccine to enhance BCG for preventing tuberculosis
Comparison: 1 MVA85A versus placebo
Outcome: 2 Active TB: started on TB treatment
Study or subgroup MVA85A Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ndiaye 2015 8/320 9/325 4.7 % 0.90 [ 0.35, 2.31 ]
Nemes 2018 5/123 3/125 1.6 % 1.69 [ 0.41, 6.93 ]
Tameris 2013 196/1399 177/1395 93.7 % 1.10 [ 0.91, 1.33 ]
Total (95% CI) 1842 1845 100.0 % 1.10 [ 0.92, 1.33 ]
Total events: 209 (MVA85A), 189 (Placebo)
Heterogeneity: Chi2 = 0.53, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours MVA85A Favours BCG alone
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Analysis 1.3. Comparison 1 MVA85A versus placebo, Outcome 3 Latent TB.
Review: MVA85A vaccine to enhance BCG for preventing tuberculosis
Comparison: 1 MVA85A versus placebo
Outcome: 3 Latent TB
Study or subgroup MVA85A Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ndiaye 2015 38/320 40/325 18.4 % 0.96 [ 0.64, 1.46 ]
Nemes 2018 1/123 4/125 1.8 % 0.25 [ 0.03, 2.24 ]
Scriba 2011 3/108 0/36 0.3 % 2.38 [ 0.13, 44.93 ]
Tameris 2013 178/1399 171/1395 79.4 % 1.04 [ 0.85, 1.26 ]
Total (95% CI) 1950 1881 100.0 % 1.01 [ 0.85, 1.21 ]
Total events: 220 (MVA85A), 215 (Placebo)
Heterogeneity: Chi2 = 1.98, df = 3 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours MVA85A Favours placebo
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Analysis 1.4. Comparison 1 MVA85A versus placebo, Outcome 4 Adverse effects of any severity.
Review: MVA85A vaccine to enhance BCG for preventing tuberculosis
Comparison: 1 MVA85A versus placebo
Outcome: 4 Adverse effects of any severity
Study or subgroup MVA85A Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Local: skin
Nemes 2018 121/123 118/125 1.04 [ 0.99, 1.09 ]
Scriba 2011 106/108 6/36 5.89 [ 2.84, 12.23 ]
Tameris 2013 1251/1399 628/1396 1.99 [ 1.87, 2.11 ]
2 Malaise
Scriba 2011 6/108 1/36 2.00 [ 0.25, 16.06 ]
3 Lethargy
Scriba 2011 6/108 2/36 1.00 [ 0.21, 4.74 ]
4 Any fever
Scriba 2011 18/108 2/36 3.00 [ 0.73, 12.30 ]
5 Vomiting
Scriba 2011 6/108 2/36 1.00 [ 0.21, 4.74 ]
0.01 0.1 1 10 100
Favours MVA85A Favours placebo
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Analysis 1.5. Comparison 1 MVA85A versus placebo, Outcome 5 Adverse effects of any severity: aggregated.
Review: MVA85A vaccine to enhance BCG for preventing tuberculosis
Comparison: 1 MVA85A versus placebo
Outcome: 5 Adverse effects of any severity: aggregated
Study or subgroup MVA85A Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ndiaye 2015 318/324 307/325 1.04 [ 1.01, 1.07 ]
Nemes 2018 (1) 105/123 30/125 3.56 [ 2.58, 4.90 ]
Scriba 2011 106/108 6/36 5.89 [ 2.84, 12.23 ]
Tameris 2013 (2) 1251/1399 628/1396 1.99 [ 1.87, 2.11 ]
0.2 0.5 1 2 5
Favours MVA85A Favours placebo
(1) Definitely related to vaccine
(2) Local adverse effects only
Analysis 1.6. Comparison 1 MVA85A versus placebo, Outcome 6 Serious adverse effects.
Review: MVA85A vaccine to enhance BCG for preventing tuberculosis
Comparison: 1 MVA85A versus placebo
Outcome: 6 Serious adverse effects
Study or subgroup MVA85A Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ndiaye 2015 1/324 0/325 17.6 % 0.00 [ -0.01, 0.01 ]
Nemes 2018 0/123 0/125 6.7 % 0.0 [ -0.02, 0.02 ]
Tameris 2013 0/1399 1/1396 75.7 % 0.00 [ 0.00, 0.00 ]
Total (95% CI) 1846 1846 100.0 % 0.00 [ 0.00, 0.00 ]
Total events: 1 (MVA85A), 1 (Placebo)
Heterogeneity: Chi2 = 1.01, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.00 (P = 1.0)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours MVA85A Favours placebo
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Analysis 1.7. Comparison 1 MVA85A versus placebo, Outcome 7 Adverse events of any severity.
Review: MVA85A vaccine to enhance BCG for preventing tuberculosis
Comparison: 1 MVA85A versus placebo
Outcome: 7 Adverse events of any severity
Study or subgroup MVA85A Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ndiaye 2015 321/324 312/325 20.8 % 1.03 [ 1.01, 1.06 ]
Nemes 2018 122/123 121/125 8.0 % 1.02 [ 0.99, 1.06 ]
Scriba 2011 (1) 1/36 1/12 0.1 % 0.33 [ 0.02, 4.93 ]
Scriba 2011 (2) 6/36 0/12 0.0 % 4.57 [ 0.28, 75.58 ]
Scriba 2011 (3) 3/36 0/12 0.0 % 2.46 [ 0.14, 44.48 ]
Tameris 2013 1120/1399 1059/1396 70.9 % 1.06 [ 1.01, 1.10 ]
Total (95% CI) 1954 1882 100.0 % 1.05 [ 1.02, 1.08 ]
Total events: 1573 (MVA85A), 1493 (Placebo)
Heterogeneity: Chi2 = 5.76, df = 5 (P = 0.33); I2 =13%
Test for overall effect: Z = 3.29 (P = 0.0010)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours MVA85A Favours placebo
(1) 2.5 10
7
PFU = 35 L
(2) 1 10
8
= 135 L
(3) 5 10
7
= 70 L
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Analysis 1.8. Comparison 1 MVA85A versus placebo, Outcome 8 Abnormal biochemical tests.
Review: MVA85A vaccine to enhance BCG for preventing tuberculosis
Comparison: 1 MVA85A versus placebo
Outcome: 8 Abnormal biochemical tests
Study or subgroup MVA85A Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nemes 2018 14/123 13/125 68.2 % 1.09 [ 0.54, 2.23 ]
Scriba 2011 (1) 13/108 4/36 31.8 % 1.08 [ 0.38, 3.11 ]
Total (95% CI) 231 161 100.0 % 1.09 [ 0.60, 1.97 ]
Total events: 27 (MVA85A), 17 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours MVA85A Favours BCG alone
(1) Three different doses of MVA85A included
Analysis 2.1. Comparison 2 Comparison of endpoints, Outcome 1 Tameris 2013: incidence of tuberculosis
(TB) according to post-hoc endpoints.
Review: MVA85A vaccine to enhance BCG for preventing tuberculosis
Comparison: 2 Comparison of endpoints
Outcome: 1 Tameris 2013: incidence of tuberculosis (TB) according to post-hoc endpoints
Study or subgroup MVA85A Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tameris 2013 (1) 32/1399 39/1395 0.82 [ 0.52, 1.30 ]
Tameris 2013 (2) 55/1399 52/1395 1.05 [ 0.73, 1.53 ]
Tameris 2013 (3) 196/1399 177/1395 1.10 [ 0.91, 1.33 ]
Tameris 2013 (4) 22/1399 20/1395 1.10 [ 0.60, 2.00 ]
0.5 0.7 1 1.5 2
Favours MVA85A Favours placebo
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(1) Endpoint 1 composite clinical endpoint
(2) Endpoint 2 composite clinical endpoint
(3) Endpoint 3 composite clinical endpoint
(4) Microbiologically confirmed
Analysis 2.2. Comparison 2 Comparison of endpoints, Outcome 2 Ndiaye 2015: incidence of TB according
to post hoc defined endpoints.
Review: MVA85A vaccine to enhance BCG for preventing tuberculosis
Comparison: 2 Comparison of endpoints
Outcome: 2 Ndiaye 2015: incidence of TB according to post hoc defined endpoints
Study or subgroup MVA85A Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ndiaye 2015 (1) 6/320 9/325 0.68 [ 0.24, 1.88 ]
Ndiaye 2015 (2) 6/320 9/325 0.68 [ 0.24, 1.88 ]
Ndiaye 2015 (3) 8/320 9/325 0.90 [ 0.35, 2.31 ]
0.01 0.1 1 10 100
Favours MVA85A Favours placebo
(1) Endpoint 1: culture/GeneXpert
(2) Endpoint 2: composite clinical outcome
(3) Commencement on anti-TB medication
A D D I T I O N A L T A B L E S
Table 1. Summary of Phase 1 studies
NCT trial
number
Route Dates Inter-
vention and
schedule
details
Country Participants
(age)
HIV Adverse events Reference
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Table 1. Summary of Phase 1 studies (Continued)
NCT00423566
ID 2002-2003 MVA85A; 1
dose
UK 14 adults
(18-45
years)
-ve 7 trials (112 par-
ticipants); com-
bined in 1 re-
port: no serious
AE attributable
to the vaccine
McShane 2004;
Rowland 2012
NCT00423839
ID 2003-2005 MVA85A; 1
dose, 2 doses
(5 × 107 pfu)
Gambia 21 adults NR No serious AE
attributable to
the vaccine
Brookes 2008;
Ibanga 2006;
Owiafe 2012
NCT00427830
ID 2003-2005 MVA85A; 1
dose (5 × 10
7 pfu)
UK 21 adults -ve No serious AE
attributable to
the vaccine
McShane 2004;
Pathan 2012;
Rowland 2012;
Tanner 2014;
Whelan 2009
NCT00427453
ID 2003-2005 MVA85A; 1
dose (5 × 10
7 pfu)
UK 10 adults -ve No serious AE
attributable to
the vaccine
Pathan 2012;
Rowland 2012
NCT00456183
ID 2005-2007 MVA85A,
(5 × 107 pfu)
UK 12
adults with
latent tuber-
culosis
-ve No vaccine-re-
lated serious AEs
7 trials (112 par-
ticipants; data
combined in 1
report)
Rowland 2012;
Sander 2009;
Tanner 2014
NCT00465465
ID 2005-2007 MVA85A; 1
dose (1 × 10
8 pfu for 12
participants,
and 1 × 10
7 pfu for 12
participants)
UK 24 adults -ve No serious AE
attributable to
the vaccine
Griffiths 2011;
Matsumiya
2013; Pathan
2007; Rowland
2012
NCT00460590
ID 2005-2008 MVA85A (5
× 107 pfu)
South Africa 36 adults
and adoles-
cents
-ve No vaccine-re-
lated serious AEs
Hawkridge
2008; Scriba
2010; Tameris
2014; Tanner
2014
NCT00480454
ID 2006-2009 MVA85A;
1 dose
MVA85A
(2.5 × 107
pfu, 5 × 107
pfu)
Groups
The Gambia 214 infants
(4 months)
NR No serious AE
judged to be re-
lated to the vac-
cine
Odutola 2012;
Ota 2011
60MVA85A vaccine to enhance BCG for preventing tuberculosis (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Table 1. Summary of Phase 1 studies (Continued)
• EPI
vaccines:
• MVA85A +
EPI:
• MVA85A +
EPI 1 week
later
NCT00395720
ID 2006-2010 MVA85A; 1
dose (5 × 10
7pfu for 10
participants,
and 1 × 10
8 pfu for 10
participants)
UK 20 adults +ve No serious AE
attributable to
the vaccine
Minassian 2011
NCT00480558
ID 2007-2011 MVA85A; 1
dose (5 × 10
7 pfu)
4 groups
with back-
ground of
• MTB
• HIV
• MTB +
HIV
• HIV
on ART
South Africa 48 adults
(18-50
years)
+ve No vaccine-re-
lated serious AEs
Scriba 2012;
Tanner 2014;
Tameris 2014
NCT00653770
ID 2007-2010 FP85A,
MVA85A (5
× 107 pfu)
UK 31 adults -ve No serious AE
attributable to
the vaccine
Rowland 2013
NCT00548444
ID 2007-2010 MVA85A; 1
dose
(1 × 108 pfu)
, adminis-
tered as 2 in-
jections (5 ×
107 pfu each
injection)
UK 12 adults -ve 7 trials (112 par-
ticipants)
; data combined
in 1 report: no
serious AE at-
tributable to the
vaccine
Porter (un-
published data:
source Rowland
2012)
NCT00731471
ID 2008-2011 MVA85A; 2
doses
(spaced by 6-
12 months)
(1 × 108 pfu)
Senegal 24 adults +ve No serious AE
attributable to
the vaccine
Dieye 2013
61MVA85A vaccine to enhance BCG for preventing tuberculosis (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Table 1. Summary of Phase 1 studies (Continued)
NCT01181856
ID
IM
2010-2011 MVA85A; 1
dose (1 × 10
8 pfu)
UK 24 adults -ve No serious AE
attributable to
the vaccine
Matsumiya
2013; Meyer
2013
NCT01194180
ID 2010-2012 MVA85A,
BCG;
1 dose (1 ×
108 pfu)
Group A:
BCG naive,
noMVA85A
Group B:
BCG naive,
MVA85A
Group
C: BCG vac-
cinated, no
MVA85A
Group
D: BCGvac-
cinated,
MVA85A.
UK 49 adults
recruited; 48
completed
study
-ve No serious AE
attributable to
the vaccine
; Harris 2014b;
Matsumiya
2013
NCT01497769
Aerosol
ID
2011-2013 MVA85A; 1
dose: 1 × 10
8, 1 × 107
pfu
UK 24 adults -ve No vaccine re-
lated serious ad-
verse effects.
Satti 2014
NCT01683773
ID 2012-2014 AERAS-402
MVA85A;
Group A: 2
doses
AERAS-402
then
MVA85A
Group B: 1
dose
AERAS-402
then
MVA85A
UK 40 adults -ve No vaccine re-
lated serious AEs
Sheehan 2015
NCT01879163
ID 2013-2014 MVA85A
IMX313;
Group
A: low-dose
MVA85A-
IMX313 (1
× 107 pfu)
Group B:
UK 30 BCG vac-
cinated
adults
-ve No vaccine-re-
lated serious AE
Minhinnick
2016
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Table 1. Summary of Phase 1 studies (Continued)
dose
MVA85A-
IMX313 (5
× 107 pfu)
Group
C: MVA85A
(5 × 107 pfu)
NCT01829490
IM 2013-2016 MVA85A,
ChAdOx1
85A;
Group A:
1 dose ChA-
dOx1 85A
Group B:
1 dose ChA-
dOx1 85A
then
MVA85A
Group C: 2
doses ChA-
dOx1 85A
then
MVA85A (1
× 108 pfu)
UK 42 adults -ve No data
reported yet
No publication
NCT01829490
NCT01954563
Aerosol
ID
2013-2016 MVA85A;
Group 1:
aerosol then
ID
Group 2: ID
then aerosol
Group 3: ID
then ID (5 ×
107 pfu)
UK 37 adults -ve No data
reported yet
Manjaly 2016
(conference ab-
stract)
NCT02532036
Aerosol
ID
2015-2018 MVA85A; 1
× 10
7 pfu aerosol
inhaled,
5 × 10
7 aerosol and
ID
UK 15 adults -ve No data
reported yet
NCT02532036
-ve: negative; +ve: positive; AE: adverse event; ART: antiretroviral therapy; BCG: bacillus Calmette-Guérin; EPI: Expanded Programme
on Immunization; ID: intradermal; IM: intramuscular; MTB: Mycobacterium tuberculosis; NR: not reported; pfu: plaque-forming
unit.
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Table 2. Adverse events risk of bias assessment methods
Criterion Assessment Explanation
Participant-reported symptoms
Was monitoring active or passive? Active
Passive
Unclear
We classified monitoring as ’active’ when authors re-
viewed participants at set time points and enquired
about symptoms
Was blinding for participants and outcome
assessors adequate?
Adequate
Inadequate
Unclear
We classified blinding as ’adequate’ when both partici-
pants and outcome assessors were blinded to the inter-
vention group, and the methods of blinding (including
use of a placebo) were described
Was outcome data reporting complete or
incomplete?
Complete
Incomplete
We classified outcome data reporting as ’complete’
when data were presented for all the time points where
it was collected
Were all participants included in reporting? Yes
No
We reported the percentage of randomized participants
included in adverse event reporting
Was the analysis independent of study
sponsor?
Yes
No
Unclear
We classified the analysis of trials sponsored by phar-
maceutical companies as independent of the sponsor
when it was clearly stated that the sponsor had no input
to the trial analysis
Laboratory tests
Number of tests undertaken - We extracted the type and number of laboratory tests
were taken
Timing of tests: was number and timing of
tests adequate?
Adequate
Inadequate
We classified the number and timing of tests as ’ade-
quate,’ when tests were taken at baseline, plus 2 other
time points within the first week after treatment, plus
the last day of the study. We classified the number of
test taken as ’inadequate,’ if either the laboratory con-
trols in the first week or controls at 4 weeks were not
performed
Reporting of test results: was reporting of
test results complete?
Complete
Incomplete
We classified reporting as ’complete’ when test results
of all time points were reported. For the trials with in-
adequate number of tests taken, we considered com-
pleteness of reporting as inconsequential, and therefore
did not record a judgement
Independence of data analysis: was data
analysis independent?
Yes
No
Unclear
We classified the analysis of trials sponsored by phar-
maceutical companies as independent of the sponsor
when it is clearly stated that the sponsor had no input
to the trial analysis
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Adapted from Bukirwa 2014.
Table 3. Differences in tuberculosis endpoint assessment
Study Endpoint 1 Endpoint 2 Endpoint 3
Tameris 2013 Any of the following criteria.
• Isolation of M tuberculosis from
any site.
• Identification of M tuberculosis
by an approved molecular
diagnostic technique from any site.
• Histopathology diagnostic for
TB disease (e.g. caseating
granulomas).
• Choroidal tubercle diagnosed
by an ophthalmologist.
• Miliary pattern on chest x-ray
in an HIV-negative infant.
• Clinical diagnosis of TB
meningitis (CSF protein
concentrations > 0.6 g/L and
pleocytosis of > 50 cells/µL with >
50% mononuclear cells) with
features of basal meningeal
enhancement and hydrocephalus on
head CT.
• Vertebral spondylosis.
• 1 smear or histology specimen
positive for auramine-positive bacilli
from a normally sterile body site.
• 1 of each of the following:
◦ evidence of mycobacterial
infection defined as 2 acid-fast
positive smears (each from a
separate collection) that were
morphologically consistent with
mycobacteria from either sputum or
gastric aspirate that were not found
to be non-tuberculous mycobacteria
bacteria on culture; QuantiFERON-
TB Gold In-tube test conversion
from negative to positive; or
tuberculin skin test ≥15 mm and
◦ radiographic findings
compatible with TB defined as ≥ 1
of the following factors identified
independently by ≥ 2 of 3
paediatric radiologists serving on a
“Included all infants who met end-
point 1 criteria; had marginally less
stringent criteria to define TB infec-
tion and household exposure.”
Any of the following numerical cate-
gories.
• Isolation of M tuberculosis from
any site.
• Identification of M tuberculosis
by an approved molecular
diagnostic technique from any site.
• Histopathology diagnostic for
TB disease (such as caseating
granulomas).
• Choroidal tubercle diagnosed
by an ophthalmologist.
• Miliary pattern on chest x-ray
in a HIV-negative infant.
• Clinical diagnosis of TB
meningitis (CSF protein > 0.6 g/L
and pleocytosis > 50/mm3 with
mononuclear cell > 50%) ora
features of basal meningeal
enhancement and hydrocephalus on
head CT.
• Vertebral spondylosis
• A single smear/histology
specimen positive for auramine-
positive bacilli from a normally
sterile body site.
• 1 of each of the following:
◦ evidence of mycobacterial
infection defined as:
⋄ 2 acid fast-positive
smears each from a separate
collection morphologically
consistent with mycobacteria from
either sputum or gastric aspirate that
are not found to be non-tuberculous
mycobacteria bacteria on culture, or
⋄ QFT conversion
from negative to positive, or
⋄ Tuberculin skin test
All participants placed on treatment
for TB by a health professional with
the intent of treating TB regardless
of whether they have met the other
efficacy endpoints
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Table 3. Differences in tuberculosis endpoint assessment (Continued)
masked review panel: calcified Ghon
focus, pulmonary cavity, hilar or
mediastinal adenopathy, pleural
effusion, or airspace opacification
and
◦ clinical manifestations
compatible with TB defined as
cough without improvement for > 2
weeks; weight loss > 10% of
bodyweight for > 2 months; or
failure to thrive, defined as crossing
> 1 complete major centile band (<
97th-90th, < 90th-75th, < 75th-
50th, < 50th-25th, < 25th-10th,
and < 10th-3rd weight-for-age
centiles) downward for > 2 months.
≥ 10 mm,a or
⋄ household contact
with AFB smear positive persona
and
◦ radiographic findings
compatible with TB defined as ≥ 1
of the following identified
independently by at least 2 out of 3
paediatric radiologists serving on a
blinded review panel: calcified
Ghon focus, pulmonary cavity,
hilar/mediastinal adenopathy,
pleural effusion, or airspace
opacification and
◦ clinical manifestations
compatible with TB defined as
either
⋄ cough without
improvement for > 2 weeks, or
⋄ weight loss ≥ 10%
of bodyweight for ≥ 2 months, or
⋄ failure to thrive
(crossing ≥ 1 entire major centile
band downward) for ≥ 2 months,
where the major centile bands are
defined as < 97th-90th, < 90th-
75th, < 75th-50th, < 50th-25th, <
25th-10th, and < 10th-3rd weight-
for-age centiles.
Andrews 2017 Revised endpoint 1 from Tameris
2013 that removed QFT conversion
from the diagnostic criteria to avoid
bias towards association with QFT
status
Not used Not used
Bunyasi 2017 Not used Not used Same definition as for Tameris 2013.
Ndiaye 2015 Any of the following numerical cate-
gories.
• Isolation of M tuberculosis from
any site.
• Identification of M tuberculosis
by an approved molecular
diagnostic technique from any site.
• Histopathology diagnostic for
TB disease (such as caseating
granulomas).
• Choroidal tubercle diagnosed
Any of the following numerical cate-
gories:
• Isolation of M tuberculosis from
any site.
• Identification of M tuberculosis
by an approved molecular
diagnostic technique from any site.
• Histopathology diagnostic for
TB disease (such as caseating
granulomas).
• Choroidal tubercle diagnosed
Same definition as for Tameris 2013.
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Table 3. Differences in tuberculosis endpoint assessment (Continued)
by ophthalmologist. by ophthalmologist.
• A single smear/histology
specimen positive for AFB from a
normally sterile body site.
• 2 acid-fast smears positive each
from a separate collection
morphologically consistent with
mycobacteria from either
pulmonary or gastric sampling that
are not found to be non-tuberculous
mycobacteria bacteria on culture,
and ≥ 1 of the following:
◦ a compatible radiographic
feature: airspace opacification,
cavity, hilar or mediastinal
adenopathy, or pleural effusion;
◦ a compatible clinical
feature, i.e. > 2 weeks of fever, night
sweats, anorexia, cough, or weight
loss (≥ 5 kg by history or noticeable
change in clothing fit); or ≥ 1
episodes of haemoptysis.
Scriba 2011 Not applicable Not applicable Not applicable
Nemes 2018 Outcomes not specified in the meth-
ods section.
In results, authors specified that 8
participants were diagnosed as TB:
“of whom one was M.tb [Mycobac-
terium tuberculosis] culture positive
and 7 were diagnosed on clinical/ ra-
diographic grounds and TB contact
history. Two of the TB cases were
QFT positive.”
Not used Not used
AFB: acid-fast bacilli; CSF: cerebrospinal fluid; CT: computerized tomography; QFT: quantiFERON; TB: tuberculosis.
aIn Tameris 2013, endpoint 2: criteria in bold indicate where different from endpoint 1.
Table 4. Differences between details of studies published prior to commencement and reported outcomes
Study Protocol Published findings Differences be-
tween protocol and
published findingsStated outcomes
pub-
lished prior to com-
Measurement of
outcome as stated a
priori
Measurement of
outcome as stated in
Reported findings
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Table 4. Differences between details of studies published prior to commencement and reported outcomes (Continued)
mencement of trial
that differ to pub-
lished outcomes
published findings
Andrews 2017 No protocol published.
Bunyasi 2017 No protocol published (extended post-trial follow-up of Tameris 2013).
Ndiaye 2015 Adverse events:
blood tests a
“Percentage
of participants with
adverse events” AEs
measured up to day
28
SAEsmeasured up to
6 months.
“Phlebotomy
for routine haemato-
logical and biochem-
ical analysis was done
at screening, before
booster vaccination,
and on days 7 and
28 after each vaccina-
tion.”
“Routine haemato-
logical and biochem-
ical test results did
not differ between
study groups (data
not shown).”
Haemato-
logical and biochem-
ical blood tests not
outlined as a measure
of safety in the study
protocol. Blood test
findings reported un-
clearly
Nemes 2018 Safety Clinicaltrials.
gov - local, regional,
and systemicAEs and
SAEs which would
be reported as cumu-
lative 12-month inci-
dences
“Infants followed for
safety end points at
weeks 1, 4, 6, and 8
after MVA85A/con-
trol vaccination and
thereafter, at weeks
9, 12, and 16 (cor-
responding to weeks
1, 4, and 8 following
delayed BCG vacci-
nation at 8 weeks of
age), and at week 52.
”
Reported total events
for AEs per group
after MVA85A and
before BCG and for
whole follow-up pe-
riod. Data including
for laboratory AEs
were not disaggre-
gated as prespecified
Data including for
laboratory AEs were
not disaggregated as
prespecified
Scriba 2011 Safetya Local and systemic
AEs for the first
week.
Diary cards Local and systemic
AEs reported on ≥ 1
day of the first 7 days
afterMVA85A vacci-
nation
None
Blood tests (days 7,
28)
Biochemi-
cal and haematologi-
cal tests (days 7, 28)
Reported num-
ber and percentages
of participants with
abnormal results and
reported that, “all ex-
cept one patient that
had elevated liver en-
zymes remained un-
resolved by day 28.”
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Table 4. Differences between details of studies published prior to commencement and reported outcomes (Continued)
Immunology ESAT-6/CFP-10 Infants converted -
suggestive of TB in-
fection but seemed to
be reported as safety
data not efficacy
Tameris 2013 Safety profile - AEsa AEs measured up to
day 28
SAEs measured
throughout follow-
up.
Collected data on
solicited and unso-
licited local and sys-
temic AEs
Active surveillance
for SAEs.
AEs broken down by
type of
event and reported in
supplementarymate-
rial.Only local events
at the injection site
were considered to be
related to the vaccine
Causal relationship
with AEs other than
local injection site re-
actions was not re-
ported
Safety profile - blood
testsa
Testing up to 28 days
postvaccination.
“Peripheral blood for
routine haematolog-
ical and biochemi-
cal tests was taken at
screening and on day
7 and day 28 after
vaccination in an ini-
tial safety cohort of at
least 330 infants.”
Not reported Primary outcomenot
reported
Efficacy of MVA85A
b
Using an endpoint
derived from epi-
demiological cohort
surveys in BCG vac-
cinated infants
Not reported
- simply stated clini-
cal endpoints ’devel-
oped.’
Composite clinical
endpoints 1, 2, 3 (see
Table 3)
Microbi-
ologically confirmed
cases reported in ap-
pendix.
The “primary effi-
cacy endpoint” was
measured using an
endpoint not derived
from cohort studies
The endpoint defini-
tion differed from all
other implied or re-
ported ways of mea-
suring efficacy in the
other
studies. The point es-
timate showed clini-
cally significant ben-
efit for endpoint 1
(no benefit seen at
the 95% confidence
level). This endpoint
was reported as the
main efficacy find-
ing. All other point
estimates show no
clinically significant
benefit or harm
69MVA85A vaccine to enhance BCG for preventing tuberculosis (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
AE: adverse events; BCG: bacillus Calmette-Guérin; ESAT-6/CFP-10: early secretory antigenic-6/culture filtrate protein-10; SAE:
severe adverse events; TB: tuberculosis.
aPrimary outcomes as outlined in study protocols.
bSecondary outcomes as outlined in study protocols.
Table 5. Summary of monitoring and reporting of adverse events
Study Participant reported adverse
events
Outcome data reporting Laboratory tests
Moni-
toring
active or
passive
Blind-
ing of
partici-
pants or
out-
come
asses-
sors
Times
data
col-
lected
Times
data re-
ported
Com-
plete/
not
com-
plete
Percent-
age of
partici-
pants
re-
ported
on
Analy-
sis inde-
pendent
of study
sponsor
Number
of tests
taken
Timing
of tests
and ade-
quacy
Com-
plete re-
porting
of test
results
Inde-
pen-
dence of
data
analysis
Scriba
2011
Active Inade-
quate
60 min,
D 2, 7,
28, 84,
and 168
D 7, 28 Incom-
plete
100% Unclear Bio-
chem-
istry and
haema-
tology
Inade-
quate
Inconse-
quential
Unclear
Ndiaye
2015
Active Inade-
quate
D 7, 28,
and
84 after
boost 3
monthly
un-
til end of
study
NR Incom-
plete
99.8% No Haema-
tology,
chem-
istry, vi-
rological
markers
Ade-
quate
Incom-
plete
No
Tameris
2013
Active Ade-
quate
Baseline,
D 7
and 28,
through-
out up
to D 84
NR Incom-
plete
99.9% No Bio-
chem-
istry and
haema-
tology
Inade-
quate
Incom-
plete
No
Nemes
2018
Active Ade-
quate
Week 1,
4, 6, 8,
16, and
52
NR Incom-
plete
85.9% Unclear Not
specified
Ade-
quate
Incom-
plete
Unclear
D: day; min: minute; NR: not reported.
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Table 6. Results of the different endpoints of active tuberculosis
Active
TB
Tameris 2013 Andrews 2017 Bunyasi 2017 Ndiaye 2015 Scriba 2011 Nemes 2018
MVA85A Placebo MVA85A Placebo MVA85A Placebo MVA85A Placebo MVA85A Placebo MVA85A Placebo
End-
point 1
a
32/
1399
(2.3%)
39/
1395
(2.8%)
58/2797 (2.1%)
with NDD
N/A N/A 6/320
(1.9%)
9/325
(2.8%)
N/A N/A 5/123
(4.1%)
3/125
(2.4%)
End-
point 2
a
55/
1399
(3.9%)
52/
1395
(3.7%)
N/A N/A N/A N/A 6/320
(1.9%)
9/325
(2.8%)
N/A N/A N/A N/A
End-
point 3
a
196/
1399
(14.
0%)
177/
1395
(12.
6%)
N/A N/A 3.3/100
pyo
(95%
CI 2.9
to 3.9)
3.0/
100 pyo
(95%
CI 2.6
to 3.5)
8/320
(2.5%)
9/325
(2.8%)
N/A N/A N/A N/A
CI: confidence interval; N/A: not applicable; NDD: no disaggregated data; pyo: person-years of observation; TB: tuberculosis.
aSee Table 3 for description of endpoints.
Table 7. Adverse effects of the MVA85A vaccine
Study MVA85A Placebo Breakdown Author
conclusions
Number of
partic-
ipants with
≥ 1 event
caused
by the in-
tervention
Total par-
ticipants
Number of
partic-
ipants with
≥ 1 event
caused by
the control
Total par-
ticipants
Detailed
AEs
MVA85A Placebo
Ndiaye
2015
318 324 307 325 Solicited
AEsa
288 235 “Solicited adverse
events were more
com-
mon in MVA85A
group and most
were local injec-
tion site reactions.
”
Nemes 2018 105b 123 30b 125 Not detailed N/A N/A “Infants
in MVA85A arm
were more likely
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Table 7. Adverse effects of the MVA85A vaccine (Continued)
to experience an
AE than in con-
trol arm. Injection
site reactions were
more frequent in
MVA85A recipi-
ents and mild.”
Scriba 2011 106c 108c 6 36 Injection
sited
106 6 “Desquama-
tion significantly
increased
with greater vac-
cine dose.”
Malaise 6 1
Lethargy 6 2
Tactile fever 18 0
Docu-
mented
fever
13 2
Vomiting 6 2
Elevated
liver enzyme
levels
13 4
Increased
white cell
count
0 1
Tameris
2013
Local 1251e 1399 Local 628e 1396 Not detailed 1251 628 None
AE: adverse event; N/A: not applicable.
aIncluded injection reactions, mild influenza-like symptoms, and regional lymphadenopathy.
bAuthors of the study reported 105 participants with at least one adverse effect in the vaccine group and 30 participants in the placebo
group, where causal relationship was defined as definite.
cAggregated between three groups receiving different doses.
d Included desquamation (scaling), pain, redness, and swelling.
eAuthors of the study reported local and systemic adverse events. Authors specified in their protocol that, “Solicited adverse events of
local injection site reactions will be considered causally related to study vaccine (adverse reaction).” Therefore, we reported such adverse
events as adverse effects. Causal relationship with other adverse events was not reported.
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Table 8. Adverse events summary table
Study Adverse events of any severity
MVA85A Placebo
Tameris 2013 1120/1399 (80.1%) 1059/1396 (75.9%)
Andrews 2017 NR NR
Bunyasi 2017 NR NR
Ndiaye 2015 321/324
(99.1%)
312/325
(96%)
Scriba 2011 2.5 × 107
pfu = 35 µL
5 × 107
pfu = 70 µL
1 × 108
pfu = 135 µL
1/36
1/36 3/36 6/36
Nemes 2018 Mild 122/123
(99.2%)
121/125
(96.8)
Moderate 62/123
(50.4%)
54/125
(3.6%)
Severe 11/123
(8.9%)
14/125
(11.2%)
NR: not reported; pfu: plaque-forming unit.
Table 9. Abnormal haematological and biochemical tests
Study Haematological blood tests Biochemical blood tests
MVA85A Placebo MVA85A Placebo
Tameris 2013 NR NR NR NR
Andrews 2017 NR NR NR NR
Bunyasi 2017 NR NR NR NR
Ndiaye 2015 NRa NRa NRa NRa
Scriba 2011 0/108b 1/36b 2.5 × 107
pfu = 35 µL
5 × 107
pfu = 70 µL
1 × 108
pfu = 135 µL
4/36
(11%)
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Table 9. Abnormal haematological and biochemical tests (Continued)
1/36
(2.8%)
3/36
(8.3%)
9/36
(25%)
Nemes 2018 NR NR 14/123 (11.4%) 13/125
(10.4%)
NR: not reported; pfu: plaque-forming unit.
aAuthors stated that routine haematological and biochemical test results did not differ between study groups but did not present data.
bOne participant had increased white cell count concurrently with an increase in alanine aminotransferase during an episode of
gastroenteritis. Authors did not describe any other case of abnormal haematological test in the rest of the participant, although it was
not stated explicitly.
A P P E N D I C E S
Appendix 1. Search strategies
Cochrane Central Register of Controlled Trials
#1 tuberculosis or TB:ti,ab,kw (Word variations have been searched)
#2 MeSH descriptor: [Tuberculosis] explode all trees
#3 MeSH descriptor: [BCG Vaccine] explode all trees
#4 “BCG vaccin*”:ti,ab,kw (Word variations have been searched)
#5 bacill* Calmette-Guerin
#6 #1 or #2 or #3 or #4 or #5
#7 “antigen 85A” or Ag85A or “modified vaccinia ankara” or MVA85A
#8 MVA85*
#9 #7 or #8
#10 #9 and #6
MEDLINE (PubMed)
#12 Search #7 and #11
#11 Search ((#8) OR #9) OR #10
#10 Search “drug therapy” [Subheading]
#9 Search randomized or placebo or randomly or trial or groups Field: Title/Abstract
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(Continued)
#8 Search “Randomized Controlled Trial” [Publication Type] OR “Controlled Clinical Trial” [Publication Type]
#7 Search #3 and #6
#6 Search 4 or 5
#5 “antigen 85A” OR Ag85A OR “modified vaccinia ankara” OR MVA85A Field: Title/Abstract
#4 “antigen 85A, Mycobacterium tuberculosis” [Supplementary Concept] or “MVA 85A” [Supplementary Concept])
#3 Search 1 or 2
#2 ((“BCG Vaccine”[Mesh]) OR (“bcg vaccin*” or “bacille Calmette-Guérin” )Field: Title/Abstract
#1 “Tuberculosis”[Mesh] or (tuberculosis or TB) Field: Title/Abstract
Embase
1 (tuberculosis or tuberculous or TB).mp.
2 tuberculosis/
3 1 or 2
4 BCG vaccine/ or BCG vaccin*.mp. or BCG vaccination/
5 3 or 4
6 MVA85A.mp.
7 antigen 85A.mp.
8 Ag85A.mp.
9 modified vaccinia virus ankara.mp.
10 modified vaccine ankara.mp.
11 6 or 7 or 8 or 9 or 10
12 5 and 11
13 (randomized or randomised or placebo or double-blind* or single-blind*).mp.
14 randomized controlled trial/ or controlled clinical trial/
15 crossover procedure/
16 13 or 14 or 15
17 12 and 16
CINAHL (EBSCOHost)
# Search terms
S1 TX ( tuberculosis or TB or BCG )
S2 TX ( (MVA85A or “antigen 85A” or “modified vaccinia ankara” )
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(Continued)
S3 TX ( (randomized trial or controlled trial or placebo or double-blind* or single-blind* )
S4 S1 AND S2 AND S3
Web of Science
# 2 TOPIC: (tuberculosis or TB or BCG) ANDTOPIC: (MVA85A or “antigen 85A” or “modified vaccinia ankara”) ANDTOPIC:
(randomized trial or controlled trial or placebo or double-blind* or single-blind*)
Timespan=All years
Search language=Auto
# 1 TOPIC: (tuberculosis or TB or BCG) AND TOPIC: (MVA85A or “antigen 85A” or “modified vaccinia ankara”)
Timespan=All years
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Changes to the author team: Taryn Young stepped down from the review author team.
We intended to pilot data extraction forms; however, given the small number of included studies we assessed the appropriateness of the
form during the actual data extraction.
In our protocol, we mentioned that the control for the type of intervention would be “BCG alone.” However, we did include in our
review studies that they used Candin® as control intervention, as this is currently used in control groups for randomized controlled
trials assessing MVA85A.
We encountered multiple different definitions of active tuberculosis in different trials. We took the approach of defining active
tuberculosis as confirmed by culture and participants starting on tuberculosis treatment to allow a consistent approach across the
included studies.
We reported adverse effects of any severity disaggregated by local reactions of the skin and systemic symptoms and we gave justification
for this decision in the result section.
The initial risk of bias for adverse event assessment tool had three options to assess completeness of reporting of participant-reported
outcomes. The options complete/incomplete/unclear were reduced to complete/incomplete as there was no difference between the
options incomplete and unclear reporting.
The detailed subgroup analysis prespecified in the protocol was not done due to too few studies.
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